

CURRICULUM VITAE

Xin Wei Wang, PhD

Senior Investigator

Deputy Director, Center for Cancer Research

Co-Director, Liver Cancer Program

Acting co-Chief, Laboratory of Human Carcinogenesis

Head, Liver Carcinogenesis Section

Center for Cancer Research, National Cancer Institute

National Institutes of Health

Office Address: 37 Convent Drive, MSC 4258
Building 37, Room 3044A
Bethesda, MD 20892
Phone: (240) 760-6858
Fax: (240) 541-4496
Email: xw3u@nih.gov
URL: <https://ccr.cancer.gov/xin-wei-wang>
URL: <https://ccr.cancer.gov/liver-cancer-program>
URL: <http://www.researcherid.com/rid/B-6162-2009>
URL: <http://orcid.org/0000-0001-9735-606X>

Education:

1977 – 1982 B.S., Shanghai First Medical College, Fudan University, Shanghai, China
1982 – 1984 M.S., Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
1986 – 1991 Ph.D., New York University, New York, New York
1991 – 1992 Postdoc Fellowship, Roche Institute of Molecular Biology, Nutley, New Jersey
1992 – 1995 Intramural Research Training Award Fellowship, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
2009 – 2010 NCI SEED (Senior Executive Enrichment & Development) IV, National Cancer Institute, Bethesda, Maryland

Employment History:

1995 – 1998 Senior Staff Fellow, National Cancer Institute, NIH, Bethesda, Maryland
1998 – 2005 Investigator and Head of Liver Carcinogenesis Unit, Laboratory of Human Carcinogenesis, NCI, Bethesda, Maryland
2002 – 2010 Adjunct Associate Professor, University of Maryland Cancer Center, Baltimore, Maryland
2005 – present Senior Investigator, National Cancer Institute, NIH, Bethesda, Maryland
2005 – present Head, Liver Carcinogenesis Section, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
2011 – 2017 Member of the Senior Biomedical Research Service, Public Health Service
2011 – 2024 Deputy Chief, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
2018 – present Co-Director, NCI CCR Liver Cancer Program
2023 – present Deputy Director, Center for Cancer Research, NCI
2024 – present Acting Co-Chief, Laboratory of Human Carcinogenesis, CCR, NCI

Professional Societies:

2004 – present American Association for Cancer Research (member)
1998 – 2006 American Association for the Advancement of Science (member)
1998 – 2018 CCR-NCI Faculty and Center for Excellence:
HIV and Cancer Virology Faculty

Cellular, Molecular and Developmental Biology Faculty
 Genetics, Genomics, and Proteomics Faculty
 Gene Expression Faculty
 Bioinformatics, Biostatistics and Computational Biology Faculty
 Molecular Targets Faculty
 Gastrointestinal Malignancies Faculty (Steering Committee)
 Metastasis Working Group
 Center for Excellence for Cancer Biology and Genomics (Steering Committee)

- 2003 – 2009 International Society of Gastroenterological Carcinogenesis (Board of Directors)
- 1998 Society of Chinese Bioscientists in America (member; lifetime)
- 2010 – 2016 SCBA DC Chapter Treasurer
- 2017 – 2018 SCBA DC Chapter President
- 2007 International Liver Cancer Association (ILCA) (Founding member)
- 2009 – 2017 American Association for the Study of Liver Diseases (member)
- 2012 – 2017 Special Interest Group on Molecular classification and signalling pathways, ILCA (Chair)
- 2018 – 2022 SCBA Hepatology Division, Executive Council member
- 2020 – 2021 SCBA Hepatology Division, President
- 2020 – present American Association for the Advancement of Science (member)

Honors and Other Special Scientific Recognition

- 1980 Best Student Award, Shanghai First Medical College
- 1984 Best Thesis Award, Committee of Pharmaceutics Sinica, Shanghai
- 1988 Travel award from American Society of Toxicology
- 1991 Meritorious Research Award, American Society of Toxicology
- 1991 – 1992 Roche Institute of Molecular Biology Postdoctoral Fellowship Award
- 1992 – 1995 NCI Intramural Cancer Research Fellowship Award
- 1998 – 2020 Federal Technology Transfer Awards (award year: 1998, 2000, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2015, 2016, 2019, 2020)
- 2004 Visiting professor, Mount Sinai School of Medicine
- 2005 Distinguished lecturer, UMBC Greenebaum Cancer Center
- 2008 Natural Sciences Award (first place), The Ministry of Education of China
- 2008 Special lectureship (keynote speaker), Chinese Medical Association
- 2009 NIH Merit Award
- 2009 NCI Outstanding Mentor Award (Mentor of Merit)
- 2010 NIH APO Outstanding Scientific Achievement Award
- 2011 Honorary Professor, Fudan University
- 2011 The SCBA Outstanding Leadership and Service Award
- 2012 Keynote Speaker, International Symposium on Clinical and Translational Cancer Research
- 2013 NIH Director's Award
- 2013 Keynote Speaker, the 22nd Asia Pacific Cancer Conference
- 2013 Keynote Speaker, International Symposium on Clinical and Translational Cancer Research
- 2013 NIH Merit Award
- 2014 Keynote Speaker, Mayo Clinic Hepatobiliary Cancer Retreat
- 2014 Blue Faery Award for Excellence in Liver Cancer Research
- 2015 Keynote Speaker, International Symposium on Infectious Disease and Signal Transduction
- 2015 NCI Director's Merit Award
- 2018 Keynote Speaker, Asan Cancer Institute Symposium
- 2018 NCI Director's Award for establishing the TIGER-LC consortium and outstanding accomplishments and leadership in team-driven liver cancer research
- 2021 Blue Faery Award for Excellence in Liver Cancer Research
- 2021 NCI Director's Award
- 2021 Keynote Speaker, HBV 2021

2022 Distinguished Service as the 2021 Division President, SCBA Hepatology Division
 2023 Keynote Speaker, 2023 CALS Symposium
 2023 Keynote Speaker, Inaugural annual symposium, Early Cancer Institute
 2023 NIH Director's Award for establishing the NCI Liver Cancer Program
 2023 NCI Annual Intramural Scientific Retreat Research Highlights Award
 2024 NCI Director's Award for Emerging Leader – NCI Champions

Administrative and Scientific Services

Institutional Service:

2001 – 06 NIH FARE Judge
 2000 – Member, NCI-UMD Tissue Resource Review Panel
 2002 – Chair, LHC Microarray Interest Group
 2005 – 10 Member, NIH-NCI HCC Clinical Steering Committee
 2005 CCR-NCI Inflammation and Cancer Initiative Discussion
 2006 Member, CCR-NCI Strategic Plan: focus group
 2007 – Member of Steering committee, the Center of Excellence in Integrative Cancer Biology and Genomics (CEICBG), CCR, NCI
 2008 CCR-NCI Staff Scientists Quadrennial Review
 2008 – 11 Member, NCI CCR Advisory Board (CAB)
 2009 CCR Grand Rounds Planning Committee
 2010 Earl Stadtman Investigator Search Committee
 2010 – 16 Steering Committee for the CCR Sequencing Facility
 2011 Member of Search Committee, Director of NCI Division of Cancer Prevention
 2010 – Member of Steering Committee, NCI GI Malignancies Faculty
 2011 CCR-NCI Bioinformatics Staff Scientists Quadrennial Review
 2012 – 17 CCR Core Facilities Task Force
 2014 Co-chair, Earl Stadtman Investigator Search Committee: Cancer Biology
 2014 Co-chair, NCI Symposium on Current Advances in Pancreatic Cancer Research and Treatment
 2014- Chair, CCR Genome Core Oversight committee
 2014 Earl Stadtman Investigator Cancer Biology Committee (co-chair)
 2015 Earl Stadtman Investigator Genomics and Systems Biology Committee
 2016 Earl Stadtman Investigator Cancer Biology Committee
 2017 Earl Stadtman Investigator Cancer Biology Committee
 2018 Chair, The committee on the 2020 NCI Annual Plan and Budget Proposal: Risk Stratification and Precision Prevention
 2019 Co-Organizer, 2019 NCI CCR LCP Scientific conference
 2021 Member, The committee on the 2023 NCI Annual Plan and Budget Proposal: Precision Prevention
 2021 Earl Stadtman Investigator Cancer Biology Committee
 2021 – 24 Member of the NIH Board of Scientific Directors
 2021 – Council member, NIH Federation of AANHPI Network (FAN)

National and International Service:

2002 Organizer, International Workshop on Human Hepatocellular Carcinoma, Bethesda, Maryland
 2003 – 09 The International Society of Gastroenterological Carcinogenesis (Board of Directors)
 2005 – 10 National Research Council Research Advisors
 2006 Co-organizer, NCI-cosponsored Symposium on liver cancer At the Shanghai-Hong Kong Liver Congress
 2007 Co-organizer, Keystone Symposia, Beijing, China
 2007 – 08 Peer Review Committee Ad-hoc Member, ACS
 2008 Co-organizer, US-Sino Symposia on Liver Cancer
 2008 Member, Poster Review Committee, 2nd ILCA Conference

2009 – 12 Peer Review Committee on Tumor Biology and Genomics, ACS
 2009 – 16 Treasurer, SCBA Baltimore-DC chapter
 2009 – Co-PI, TIGER-LC consortium
 2010 – 17 Review panelist, Italian Association Cancer Research
 2010 – 12 US-China Biomedical Research Cooperation Working Group
 2010 – 14 AASLD Experimental Hepatobiliary Neoplasia Committee
 2011 – 16 ILCA Abstract Review Committee
 2011 Provocative Question Initiative workshop
 2011 NIH ZRG1 F09 Review Committee
 2012 – 13 International Scientific Advisory Committee, Asia-Pacific Primary Liver Cancer Expert (APPLE)
 2012 – 17 Chair, Molecular classification and signaling pathways Special Interest Group, ILCA
 2013 – 17 Governing Board Member, ILCA
 2013 – 17 Associate Chair, Membership Committee, ILCA
 2014 Co-organizer, 2nd NCI-Pancreatic Cancer Symposium
 2015 Co-organizer, 3rd NCI-Pancreatic Cancer Symposium
 2016 Co-organizer, Pre-conference workshop: Pre-clinical models of HCC: from target identification to clinical trials. ILCA 10th Annual Conference
 2016 – 17 President, SCBA Baltimore-DC chapter
 2016 – External Advisory Board, Mayo Clinic SPORE in hepatobiliary cancer (P50 PAR-14-353)
 2017 – 22 Executive Council, SCBA Hepatology Division
 2018 Co-organizer, Molecular Biology in Single Cells Symposium
 2018 – 23 Co-PI, Liver Cancer Moonshot Initiative
 2020 – 21 President, SCBA Hepatology Division
 2019 – 21 Co-organizer, Keystone Symposium on Cancer Stem Cells: Advances in Biology and Clinical Translation
 2021 Chair, SCBA Hepatology Division Annual Symposium

Editorial board

2002 – 2005 *Carcinogenesis*
 2008 – 2017 *Hepatology*
 2010 – 2016 *PLoS ONE* (Academic Editor)
 2010 – present *International Journal of Biological Sciences* (Executive Editor)
 2011 – present *Cell & Bioscience* (Editor)
 2011 – 2019 *Molecular Carcinogenesis* (Associate Editor)
 2013 – *Hepatic Oncology*
 2013 – 2014 *Frontiers in Cell and Developmental Biology* (Associate Editor)
 2014 – 2023 *Journal of Hepatocellular Carcinoma* (Associate Editor in Chief)
 2022 – 2024 *Hepatology*

Grant reviewer

1998 – 2000 *Cancer Research Campaign*
 2003 – 2011 *Cancer Research UK*
 2001 *Jeffress Memorial Trust*
 2003 – 2017 *Italian Association for Cancer Research*
 2004 – 2010 *Research Grants Proposal of Hong Kong*
 2006 *NIAID, NIDDK, review panels*
 2007 – 2013 *ACS Study Section on Tumor Biology and Genomics*
 2009 *The Challenge Grant RFA*
 2021 *The NIH Cancer Molecular Pathobiology Study Section*

Editorial services (Peer Reviewer, 1995 –)

(Listed major journals with impact factors >10 from over 30 journals)

Cancer Cell, Cancer Cell Report, Cell, Cell Stem Cell, Gastroenterology, Genes & Development, Gut, Immunity, Journal of Clinical Investigation, Journal of Clinical Oncology, Journal of Hepatology, Journal of National Cancer Institute, Hepatology, Nature Cancer, Nature Cell Biology, Nature, Nature Communications, Nature Medicine, Nature Methods, New England Journal of Medicine, Proc. Natl. Acad. Sci. USA, Science, Science Translational Medicine

Teaching Service

Preceptor, HHMI-NIH Research Scholars Program:

1994 – 1995 Heidi Yeh, MD, Surgical Director of thre Pediatric Transplant Program, Massachusetts General Hospital, Associate Professor of Surgery, Harvard Medical School
1995 – 1996 Michael K. Gibson, MD/PhD, Associate Professor, Director of Translational Research for Head and Neck Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN
1996 – 1997 Nissim Khabie, MD, ENT Otolaryngologist, Minneapolis, MN
1997 – 1998 Anne M. Manicone, MD, Associate Professor, University of Washington
2003 – 2004 Brian D. Zipser, MD, Diagnostic Radiologist, Lynwood, CA
2006 – 2008 Huong Giang H. Nguyen, MD/PhD, Dermatologist, Washington DC
2007 – 2008 Fei Dong, MD, Assistant Professor of Pathology, Brigham and Women’s Hospital, Boston, MA

Biotechnology Program in M.S. at Georgetown University

2008 – 2009 Xiaoyu Liang, Research Associate, Columbia University
2010 Jie Ao, PhD student, Sate University of New York at Buffalo
2013 Satish Babu Agadkar, M.S., Graduate Student, Georgetown University

Guest lecturer, the Topics in Molecular Epidemiology course

2000-04 Georgetown University Medical School

Thesis Advisor:

1996 Jill Coursen, MS, Hood College
2002 Qinghai Ye, MD/PhD, Shanghai Medical University
2006 Huliang Jia, MD/PhD, Fudan University
2007 Guoling Lin, MD/PhD, Fudan University
2008 Jiong Shi, MD/PhD, Fudan University
2012 Lei Yu, MD/PhD, Fudan University
2014 Sonya Parpart, PhD, NIH-Georgetown University Graduate Partnership
2021 Subreen Khatib, PhD, NIH-Georgetown University Graduate Partnership
2023 Zeynep Kacar, PhD, NCI-UMD Graduate Partnership

Thesis Committee:

1999 Joo-Yeon Yoo, PhD, University of Maryland
2013 Giang Nguyen, PhD, Oxford University

Mentorship Committee:

2018 – Liqin Zhu, PhD, Assistant Professor, St. Jude Children’s Research Hospital
2017 – 19 Carla Zeballos, MD; PhD thesis committee, University of Texas Health Science Center at San Antonio
2016 – Chun Zhang Yang, PhD, Tenure Track Investigator, NOB, CCR, NCI
2019 – Changqing Xie, MD, PhD, Physician-Scientist Early Investigator, TGIMB, CCR, NCI
2021 – Drew Pratt, MD, Physician-Scientist Early Investigator, LP, CCR, NCI
2022 – Lichun Ma, PhD, Earl Stadtman Tenure Track Investigator, CDSL, CCR, NCI

Current Lab members:

Marshonna Forgues, BA (1998 – present), Lab maneger
Anuradha Budhu, PhD (2002 – present), Senior Associate Scientist

Man-Hsin (Cindy) Hung, MD, PhD (2017 – present), Research Fellow
Limin Wang, PhD (2019 – present), Staff Scientist
Rebecca Whitney Leet Do, PhD (2021 – present), iCURE Postdoctoral fellow
Farid Rashidi, PhD (2022 – present), Postdoctoral fellow
Yuto Shiode, MD, PhD (2022 – present), Postdoctoral fellow
Theresa Ewa, BS (2022 – present), NIH-OxCam PhD candidate
Vijay Putatunda, MD (2022 – present), Surgical Oncology Fellow
Atlas Mashayekhi Sardoo, PhD (2023 – present), Bioinformatician
Aryan Neupane, PhD (2023 – present), Postdoctoral fellow affiliated with LCP
Christine Ma, BA (2023 – present), Technician, Human VirScan Core
Qin Li, PhD (2024 – present), Postdoctoral fellow

Former Lab members and Current Status:

Postdoctoral Fellows:

Chuan-Ging Wu, MD/PhD (1998 – 2001), Staff Scientist, FDA
Teh-Ia Huo, MD (2000 – 01), Professor, Yang Ming University
Jin Woo Kim, PhD (2001 – 04), Principal Scientist, Panagene, Inc., Deajeon, Korea
Wei Wang, PhD (2003 – 05), Senior Staff Fellow, FDA/CBER
Siritida Rabibhadana, PhD (2005), Senior Scientist, Chulabhorn Research Institute, Thailand
Supornrat Pulleium, BA (2005), Research staff, Chulabhorn Research Institute, Thailand
Vivian Takafuji, PhD (2004 – 06), Director, Balanced Being Therapies, LLC
Mi Jung Lim, PhD (2005 – 06), Senior Scientist, Biology Laboratory, South Korea
Lei Zhao, MD/PhD (2007 – 08), Professor, Clinical Director, Shandong Provincial Tumor Hospital and Institute of Oncology
Taro Yamashita, MD/PhD (2005 – 08), Associate Professor, Kanazawa University
Naoki Oishi, MD/PhD (2010 – 12), Associate Professor, Kanazawa University
Stephanie Roessler, PhD (2006 – 12), Group leader, Institute of Pathology, University Hospital, University of Heidelberg
Xuelian Zhao, PhD (2008 – 13), Co-Founder/CEO, EliteImmune, Corp. Gaithersburg, MD
Junfang Ji, MD/PhD (2006 – 13), Professor, Life Sciences Institute, Zhejiang University, China
Atsushi Takai, MD/PhD (2011 – 15), Assistant Professor, Kyoto University Medical School, Kyoto, Japan
Takamitsu Sasaki, PhD (2013 – 15), Associate Professor, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan
Juling Ji, MD/PhD (2012 – 14), Chair, Professor, Department of Pathology, Medical School of Nantong University, Nantong, China
Kosuke Kaji, MD, PhD (2014 – 15), Assistant Professor, Nara Medical University, Kashihara, Nara, Japan
Jittiporn Chaisaingmongkol, PhD (2013 – 15), Senior scientist, Chulabhorn Research Institute, Bangkok, Thailand
Hyun Goo Woo, MD, PhD (2015 – 16), Associate Professor, Ajou University School of Medicine, Suwon, South Korea
Dan Taksony Solyom Høgdall, MD (2016), Postdoctoral fellow, University of Copenhagen, Denmark
So Mee Kwon, PhD (2014 – 16), Ajou University School of Medicine, Suwon, South Korea
Yotsawat Pomyen, PhD (2015 – 18), Senior scientist, Chulabhorn Research Institute, Bangkok, Thailand
Hongping Zheng, PhD (2015 – 17), Chief Technology Officer, Macau Ahavagen Biotechnology Co., LTD. Guangzhou, China
Valerie Fako Miller, PhD (2014 – 17), Director of the Office of Postdoctoral Affairs, University of Illinois at Chicago
Enkhjargal Bayarsaikhan (2017 – 18), Director, General Laboratory Department, National Cancer Center of Mongolia
Maria Olga Hernandez, PhD (2015 – 18), Research Scientist, Single Cell Analysis Facility, Frederick National Laboratory for Cancer Research
Na Zhao, PhD (2017 – 18), Associate Professor, Tianjin Medical University General Hospital

Hien Dang, PhD (2012 – 18), Assistant Professor, Sidney Kimmel Medical College, Thomas Jefferson University
Jinping Liu, PhD (2016 – 19), Research Associate, University of Pennsylvania
Sean Martin, DO (2017 – 19), Surgical fellow in liver transplant and hepatobiliary program, University of Southern California
Dana Dominguez, MD (2018 – 20), Clinical fellow, University of California San Francisco, Department of Surgery
Sophia Franck, MD, PhD (2018 – 20), Clinical fellow, Department of Gastroenterology, University Medical Center Hannover
Eun Ju Cho, MD (2020 – 21), Associate Professor, Division of Gastroenterology, Department of Internal Medicine, Seoul National University Hospital
Julian Candia, PhD (2018 – 21), Staff Scientist, NIA, NIH
Lichun Ma, PhD (2018 – 22), NIH Stadtman Investigator, Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute
Ching-Wen Chang, PhD (2018 – 23), Assistant Professor, Taipei Medical College
Amanda Craig, PhD (2019 – 23), Senior Scientist, AstraZeneca
Shay Behrens, MD (2021 – 23), NCI Surgical Oncology Fellow, Oregon Health and Sciences University
Jeng-Fan Lo, PhD (2023), Professor, National Yang Ming Chiao Tung University
Wei Yan, PhD (2023), Associate Professor, the College of Animal Science and Technology of China Agricultural University and the Sanya Institute of China Agricultural University
Maruhen Silveira, PhD (2021 – 2023), Postdoctoral fellow, NCI

Lab Technicians:

Jill D. Coursen, MS (1997 – 98), Lab manager, NIH
Zhipeng Yu, BA (2006 – 15), Retired

MD/PhD Students:

Qinghai Ye, MD/PhD (2002), Professor, Liver Cancer Institute, Shanghai
Huliang Jia, MD/PhD (2005 – 06), Professor, Huashan Hospital, Fudan University, Shanghai
Guoling Lin, MD (2007 – 08), Assistant Professor, Zhejiang University
Fei Dong, MD (2007 – 08), Instructor in Pathology, Brigham and Women’s Hospital
Jiong Shi, MD/PhD (2008 – 09), Assistant Professor, Nanjing University
Lei Yu, MD/PhD (2010 – 12), Attending physician, Liver Cancer Institute, Fudan University
Bahadir Ozdemir, PhD (2011 – 2012), Software Engineer, Google LLC, Video Ads
Sonya Parpart (2010 – 2014), PhD, Senior Director, GRAIL, Inc.
Becky Haiyang Wang, PhD (2017 – 18), Research Fellow, Stem Cell and Regenerative Medicine Lab, Institute of Health Service and Transfusion Medicine, Beijing
Mingda David Su, MD (2018), Private practice in General Surgery, Urbana, Illinois
Subreen Khatib, PhD (2017 – 21), Associate Strategy Consultant, Triangle Insights Group, Durham, NC.
Yue Dong, MS (2021 – 23), University of Maryland PhD candidate at Statistics
Zeynap Kecar, MS (2019 – 2023), Instructor, American University
Wing Yan (Becky) Yuen, BS, MPh (2022 – 2023), UMD-NCI GPP PhD candidate

Postbac Fellows:

Ann Tseng, MD (1998 – 99), Chief Medical Officer, Neighborhood Health Center, Portland, OR
Jessica Sime, PhD (2001 – 02), Northwestern University Medical School
Vinay Rao, DO (2008 – 09), Assistant Professor of Medicine, Yale School of Medicine, New Haven, CT
Mia R Kumar, MS (2009 – 20), Strategic Account Manager, Taconic Biosciences, San Francisco
Billie Bian, BA (2014 – 15), PhD student, Icahn School of Medicine at Mount Sinai
Edward Duqum, DO (2015 – 16), Internist, Creve Coeur and Mercy Hospital, MO
Evan Maestri, BS (2021 – 22), PhD student, Stanford University
Aleesha Jacob, BA (2021 – 22), Postbac
Mahler Revsine, BS (2021 – 23), PhD student, Johns Hopkins University

MS and Summer Students:

Haress Rahim, DDS (1999), Dentist, Bloo Dental, Ashburn, VA
Lily Wong (1999, 2000)
Michele Abbasi, MD (2000)
David M. Salvay, MD (2000), Ophthalmologist, Hoag Hospital, Newport Beach, CA
Alice Uy (2000, 2001)
Shabina Siddique Ahmed, MD (2000, 2001), Endocrinologist, Suburban Hospital, Bethesda, MD
Lavanya Viswanathan, MD (2002), Assistant Professor, Uniformed Services University of the Health Sciences, Bethesda, MD
Nicholas Younes (2005)
Mindy Wei (2006), Undergraduate student, University of Maryland
Andy Chen (2006), Undergraduate student
Bhumi Patel (2006, 2007, 2008), Premed student,
Louie Zhou (2007), Premed student, University of Pennsylvania
Xiaoyu Liang (2009), PhD student, Columbia University
Jie Ao, BA (2010), PhD student, State University of New York at Buffalo
Ricklie Davis, MD (2009, 2010), Resident Physician, George Washington University
Luhe Mian (2010), Undergraduate student, University of Virginia
Shota Yasukura (2012), MD student, Kyoto University Medical School
Satish Babu Agadkar, M.S. (2012), Graduate Student, Georgetown University
Jayne Liu (2013), Undergraduate student, University of Michigan
Keiry Rodriguez (2013), Undergraduate student,
Bowranigan Tharmalingam (2014), Undergraduate student, Cornell University
Heelah Gholian (2015, 2016), Summer Intern, Bnos Yisroel of Baltimore
Bret Robinson (2015), Summer Intern, the University of North Carolina at Chapel Hill
Lucy Knight (2015 – 16), Intern, University of Oxford
Santiago Sanchez (2016), Summer Intern, University of Texas at Austin
Benjamin Davies (2016), Summer Intern, University of Cincinnati
Aparna Konde (2017), Summer Intern
Ravinder Parhar (2017 – 18), Undergraduate student, University of Oxford
Shiqi Shen, MD (2018 – 19), Visiting fellow
Kathy Wang (2022, 2023), Graduate student, Georgetown University

Grant Support:

1998 – 2000	Mechanism of liver carcinogenesis; DBS Budget Allocation, NCI, NIH (PI)
2000 – 2008	Mechanism of liver carcinogenesis; CCR Budget Allocation, NCI, NIH (PI)
2008 – 2013	Molecular signatures for liver cancer diagnosis and treatment stratification; Z01 C 010313, NCI, NIH (PI)
2008 – 2013	The identification of human hepatocellular carcinoma metastasis genes; Z01 BC 010877, NCI, NIH (PI)
2008 – 2013	The role of cancer stem cells in liver cancer heterogeneity and subtypes; Z01 BC 010876, NCI, NIH (PI)
2008 – 2013	Mechanism of viral hepatitis-mediated hepatocarcinogenesis; Z01 BC 005793, NCI, NIH (PI)
2010	Comprehensive metabolomic and integrative profiling of hepatocellular carcinoma. NCI Director's Innovation Award (co-PI); \$10,000
2013 – 2017	Molecular signatures for liver cancer diagnosis and treatment stratification; Z01 C 010313, NCI, NIH (PI)
2013 – 2017	The identification of human hepatocellular carcinoma metastasis genes; Z01 BC 010877, NCI, NIH (PI)
2013 – 2017	The role of cancer stem cells in liver cancer heterogeneity and subtypes; Z01 BC 010876, NCI, NIH (PI)
2016	Oncogenic activation of nonsense-mediated decay in hepatocellular carcinoma. NCI Director's Innovation Award (co-PI); \$10,000

- 2017 Identification of unique viral-host interaction signatures linked to early onset of hepatocarcinoma by VirScan. NCI Director's Innovation Award (co-PI); \$10,000
- 2017 – 2021 Roles of hepatic stellate cells, extracellular vesicles, and tumor microenvironment in viral hepatitis-related hepatocellular carcinoma. 1 R01 CA214145-01, NCI, NIH (PI); \$375,000
- 2017 The Genomic Landscape of Hepatitis D-related Hepatocellular Carcinoma Among Mongolian Patients. CRDF Global on U.S.-Mongolia Pilot Collaborative Award Program, sponsored by NCI and NIAID; (co-PI); \$49,800
- 2017 Liver cancer: biomarker discovery, pathogenesis and animal models. NIH DDIR Innovation Award Program (co-PI); \$77,815 (direct cost)
- 2017 – 2021 Molecular signatures for liver cancer diagnosis and treatment stratification; Z01 C 010313, NCI, NIH (PI)
- 2017 – 2021 The identification of human hepatocellular carcinoma metastasis genes; Z01 BC 010877, NCI, NIH (PI)
- 2017 – 2021 The role of cancer stem cells in liver cancer heterogeneity and subtypes; Z01 BC 010876, NCI, NIH (PI)
- 2018 – 2023 Pathway Specific Functional Biomarkers for the Early Detection of Liver Cancer; 1U01CA230690-01, NCI, NIH (co-PI)
- 2020 – 2024 Synergy Award for Liver tumor-associated microbiome and its role in cancer progression and therapy; CCR FLEX Program (co-PI)
- 2021 – 2025 Molecular signatures for liver cancer diagnosis and treatment stratification; Z01 C 010313, NCI, NIH (PI)
- 2021 – 2025 The identification of human hepatocellular carcinoma metastasis genes; Z01 BC 010877, NCI, NIH (PI)
- 2021 – 2025 The role of cancer stem cells in liver cancer heterogeneity and subtypes; Z01 BC 010876, NCI, NIH (PI)

Patents Issued:

- U.S. Patent No. 5,985,829. Screening assays for compounds that cause apoptosis. Inventors: Curtis C Harris, Xin Wei Wang, and J.H.J. Hoeijmakers
- U.S. Patent No. 6,602,979. Screening assays for compounds that cause apoptosis. Inventors: Curtis C Harris, Xin Wei Wang, and J.H.J. Hoeijmakers
- U.S. Patent No. 6,613,883. Screening assays for compounds that cause apoptosis and related compounds. Inventors: Curtis C Harris, Xin Wei Wang, and J.H.J. Hoeijmakers
- U.S. Patent No. 6,613,318. Methods for identifying inhibitors of GADD45 polypeptide activity, and inhibitors of such activity. Inventors: Wang; Xin Wei, Harris; Curtis C., Fornace, Jr.; Albert J., Coursen; Jill D., Zhan; Qimin
- U.S. Patent No. 7,125,850. Methods for identifying inhibitors of GADD45 polypeptide activity, and inhibitors of such activity. Inventors: Wang; Xin Wei, Harris; Curtis C., Fornace, Jr.; Albert J., Coursen; Jill D., Zhan; Qimin
- U.S. Patent No. 7,338,807. Screening assays for compounds that cause apoptosis. Inventors: Curtis C Harris, Xin Wei Wang, and J.H.J. Hoeijmakers
- U.S. Patent No. 7,005,419. Methods for identifying inhibitors of GADD45 polypeptide activity and inhibitors of such activity. Inventors: Wang; Xin Wei, Harris; Curtis C., Fornace, Jr.; Albert J., Coursen; Jill D., Zhan; Qimin
- U.S. Patent No. 7,438,892. Methods for identifying inhibitors of GADD45 polypeptide activity and inhibitors of such activity. Inventors: Wang; Xin Wei, Harris; Curtis C., Fornace, Jr.; Albert J., Coursen; Jill D., Zhan; Qimin
- U.S. Patent No. 7,803,380. Compositions and methods for diagnosis and treatment of tumors. Inventors: Vivian Takafuji, Xin Wei Wang
- U.S. Patent No. 8,247,183. Compositions and methods for diagnosis and treatment of tumors. Inventors: Vivian Takafuji, Xin Wei Wang, Paul K. Goldsmith
- US Patent No. 8,252,538. MicroRNA expression signature for predicting survival and metastasis in hepatocellular carcinoma: Xin Wei Wang, Anuradha Budhu, Zhao-You Tang, Carlo Croce.
- U.S. Patent No. 8,465,917. Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells. Xin Wei Wang, Junfang Ji, Taro Yamashita, Carlo Croce
- U.S. Patent No. 8,568,977. Compositions and methods for diagnosis and treatment of tumors. Inventors: Vivian Takafuji, Xin Wei Wang, Paul K. Goldsmith

European Patent No. EP 2152900 A4. Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells. Xin Wei Wang, Junfang Ji, Taro Yamashita, Carlo Croce
U.S. Patent No. 8,735,082 and 9,394,358. Gene signature for predicting prognosis of patients with solid tumors. Xin Wei Wang and Stephanie Roessler
European Patent No. 09752261.9. Gene signature for predicting prognosis of patients with solid tumors. Xin Wei Wang and Stephanie Roessler
Japanese Patent No. 5,745,401. Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy. Xin Wei Wang, Carlo Croce, Zhao-You Tang, and Hui-Chuan Sun
U.S. Patent No. 11,306,362 (2022); Gene signature predictive of hepatocellular carcinoma response to transcatheter arterial chemoembolization (TACE)

Patents Pending:

U.S. Patent application, 60/732,332 (2005); Method of Screening for hepatocellular carcinoma
U.S. Patent application (2006); Methods of determining the prognosis of an adenocarcinoma
Provisional Patent application, 60/884,052 (2006); Methods of determining the prognosis of hepatocellular carcinoma
Provisional Patent application, 61/131,800 (2008); Use of microRNA-26 as a predictive marker for hepatocellular carcinoma clinical outcome and response to interferon therapy
Provisional Patent application 62/292,789 (2016); Gene signature predictive of hepatocellular carcinoma response to transcatheter arterial chemoembolization (TACE)
Provisional Patent application; 62/914,138 (2019); NIH Ref. E-174-2019-0-US-01; A viral exposure signature for detection of early-stage hepatocellular carcinoma
PCT application, No. PCT/US2020/055077 (2020). A viral exposure signature for detection of early-stage hepatocellular carcinoma.
U.S. Patent Application No. 17/766,015 (2022). A viral exposure signature for detection of early-stage hepatocellular carcinoma.

PHS Employee Inventions:

U.S. Patent application No.: 60/370,895 (2002); International No.: PCT/US2003/010783; Methods of diagnosing potential for metastasis or developing hepatocellular carcinoma or identifying therapeutic targets. Inventors: Xin Wei Wang, Qing-Hai Ye, Jin Woo Kim
U.S. Patent application (2005); Compositions and Methods for Diagnosis and Treatment of Metastatic Disease
U.S. PHS Employee Invention. The Establishment of telomerase-immortalized human liver epithelial cell lines. Inventors: Xin Wei Wang, Curtis C Harris
Provisional Patent application 61/323,420 (2010); Diagnostic and prognostic HCC-related metabolites
U.S. PHS Employee Invention (2022). A potential protective effect of shared antigens of rhinoviruses and enteroviruses against hepatocellular carcinoma.

Major Invited Talks

1992-2000

1. “Role of TGFβ1 in cell growth regulation”. NCI, Bethesda, MD, May 1992
2. “HBV and liver cancer”. Life Sciences Symposium on Human Genetics, Association for Chinese Scientists in America, the Great Washington Chapter, April 1993
3. “Functional interaction between p53 and TFIID”. INSERM Unit, University of Strasbourg, Strasbourg, France, May 1994
4. “Role of p53 in DNA repair and apoptosis”. Department of Cell Biology and Genetics, Medical Genetics Center, Erasmus University, Rotterdam, Netherlands, August 1994

5. "Functional interaction between p53 and TFIID". Symposium on DNA Repair and Human Syndrome, NIH Research Festivals, September 1994
6. "Functional interaction between p53 and TFIID". DNA repair interest group, NIH, Bethesda, MD, March 1995
7. "Functional interaction between p53 and TFIID". Genetic Susceptibility and Molecular Carcinogenesis, AACR, Keystone, January 1996
8. "Functional interaction between p53 and HBx". 1996 Shanghai International Symposium on Liver Cancer & Hepatitis, Shanghai, China, May 1996
9. "Functional interaction between p53 and TFIID". Department of Pathology & Oncology, University of Maryland Cancer Center, Baltimore, MD, May 1996
10. "Functional interaction between p53 and TFIID". IASLC Workshop, Nancy, France, July 1996
11. "p53 and TFIID". Symposium on apoptosis, Scanning Microscopy International, Chicago, IL, May 1997
12. "Role of Gadd45 in G2/M cell cycle checkpoint control". Cancer genetics and tumor suppressor genes conference, Frederick, MD, July 1997
13. "p53 and genomic instability". National Cancer Institute, Bethesda, MD, September 1997
14. "p53, DNA helicases and genomic instability". XVIII International Congress of Genetics, Beijing, China, August 1998
15. "p53, DNA helicases and genomic instability". The 5th International Symposium on Dendritic Cells in Fundamental Clinical Immunology, Pittsburgh, PA, November 1998
16. "p53, DNA helicases and genomic instability". The National Capital Area Branch of the Society for In Vitro Biology, Beltsville, MD, December 1998
17. "Nuclear-cytoplasm trafficking and oncogenesis". The 14th Aspen Cancer Conference, Aspen, CO, July 1999
18. "p53 and Bloom syndrome". Symposium on DNA Repair and Apoptosis, NIH Research Festivals, Bethesda, MD, September 1999
19. "Role of Gadd45 in G2/M cell cycle checkpoint control". Department of Biochemistry and Molecular Biology, University of Maryland, Baltimore, MD, March 2000
20. "Nuclear-cytoplasm trafficking and oncogenesis". Graduate Class for Topics in Molecular Epidemiology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, May 2000
21. "Nuclear-cytoplasm trafficking and oncogenesis". Department of Pathology, Virginia Commonwealth University, Richmond, VA, September 2000

2000 – 2005

22. "Molecular profiling of human hepatocellular carcinoma". Graduate Class for Topics in Molecular Epidemiology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, April 2001

23. "Molecular pathogenesis of liver cancer". The 9th International Congress of Toxicology, Brisbane, Australia, September 2001
24. "Nucleocytoplasmic transport, spindle assembly and chromosomal stability". The 16th Aspen Cancer Conference, Aspen, CO, July 2001
25. "Molecular profiling of human hepatocellular carcinoma". Multicenter Hemophilia Cohort Study-II, Washington, DC, January 2002
26. "Molecular profiling of human hepatocellular carcinoma". Molecular Genomics 2002: profiling of gene expression, Galveston, TX, 2002
27. "Molecular profiling of human hepatocellular carcinoma". Graduate Class for Topics in Molecular Epidemiology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, March 2002
28. "Molecular profiling of human hepatocellular carcinoma". Clinical Center, NIH, Bethesda, MD, May 2002
29. "Molecular profiling of human hepatocellular carcinoma". FASEB Summer Research Conference on "Mechanisms of Liver Growth, Differentiation and Molecular Pathogenesis of Hepatic Diseases, Snow Mass, CO, July 2002
30. "Molecular profiling of human hepatocellular carcinoma". International Workshop on Human Hepatocellular Carcinoma, Bethesda, MD, September 2002
31. "Molecular pathogenesis of human hepatocellular carcinoma". Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, October 2002
32. "Molecular pathogenesis of human hepatocellular carcinoma". Cancer Institute/Hospital, Chinese Academy of Medical Sciences, Beijing, China October 2002
33. "Molecular profiling of human hepatocellular carcinoma". Thomas Jefferson University, Jefferson Center for Biomedical Research, Doylestown, PA, January 2003
34. "Molecular pathogenesis of human hepatocellular carcinoma". Bernie Carter Center for Immunology Research, University of Virginia Health Sciences Center, Charlottesville, VA. March 2003
35. "Lesson learned from molecular profiling of human hepatocellular carcinoma". Graduate Class for Topics in Molecular Epidemiology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, May 2003
36. "Lesson learned from molecular profiling of human hepatocellular carcinoma". The Thirteenth International Symposium of Hiroshima Cancer Seminar, Hiroshima, Japan, October 2003.
37. "Lesson from molecular profiling of human hepatocellular cancer". Symposium on molecular diagnosis of human cancer sponsored by Shanghai Medical Association, Shanghai, China, November 2003.
38. "Lesson learned from molecular profiling of human hepatocellular cancer". The GW Cancer Institute, the George Washington University Medical Center, Washington DC, January 2004.
39. "Lesson learned from molecular profiling of human hepatocellular carcinoma". Hong Kong-Shanghai International Liver Congress 2004, Hong Kong, China, February 2004.

40. “Metastatic signature of hepatocellular cancer”. The 19th Aspen Cancer Conference, Aspen, Colorado, August 2004.
41. “Molecular signature of liver cancer metastasis”. The 3rd International Conference on Gastroenterological Carcinogenesis, Sapporo, Japan, August 2004.
42. “Molecular profiling of chronic liver diseases and hepatocellular cancer”. The 35th Environmental Mutagen Society Annual Meeting, Pittsburgh, Pennsylvania, October 2004.
43. “Molecular profiling of chronic liver diseases and hepatocellular cancer”. Guest speaker, Division of Gastroenterology and Liver Diseases, Mount Sinai School of Medicine; New York, New York, October 2004.
44. Keystone Symposia Program Committee Meeting (as an ad hoc member), Keystone, Colorado, January 2005.
45. Frontiers in Oncology Seminar Series: “Progress on molecular diagnosis and molecular targets for human hepatocellular carcinoma”. Distinguished lecturer, University of Maryland Greenebaum Cancer Center, Baltimore, MD, March 2005.
46. “Molecular signatures of metastatic hepatocellular carcinoma”. Invited speaker, The National Cancer Institute Liver Cancer Symposium, Bethesda, MD, April 2005
47. “Metastatic signature of hepatocellular carcinoma” in New Concepts in Organ-Site Research. Invited speaker, The 96th Annual Meeting of the American Association for Cancer Research, Anaheim, CA, April 2005
48. “Cytokines in human hepatocellular carcinoma”. Invited speaker, The NCI inflammation and liver cancer conference, Bethesda, MD, December 2005

2006 – 2010

49. “Hepatocellular Carcinoma: State-of-the-Art on molecular diagnosis and therapeutic opportunity”. Speaker and co-organizer, NCI Symposium, Shanghai-Hong Kong International Liver Congress 2006, Shanghai, China, March 2006
50. “Role of liver microenvironment in metastasis”. Invited speaker, CNIO Cancer Conference, Madrid, Spain, May 2006
51. “Liver microenvironment and hepatocarcinogenesis”. Invited speaker, the 4th International Society of Gastroenterological Carcinogenesis Conference, Hawaii, August 2006
52. “Inflammation, cytokines and hepatocellular carcinoma”. Invited speaker, The GTCbio 5th annual conference on Cytokines and Inflammation, Breckenridge, CO, January 2007
53. “The art of liver cancer prognosis: from the viewpoint of biology” in New Concepts in Organ-Site Research. Invited speaker, The 96th Annual Meeting of the American Association for Cancer Research, Los Angeles, CA, April 2007
54. “Hepatocellular Carcinoma: A Genomic Perspective”. Invited speaker, Center for Human Genomics Seminar Series, Wake Forest University School of Medicine, May, 2007
55. “Interrogating the genome in hepatocellular carcinoma”. Invited speaker, Cancer Genetics and Epidemiology Program Monthly Seminar Series, the Lombardi Cancer Center at Georgetown University, Washington, DC, June 2007

56. “Interrogating the genome in hepatocellular carcinoma”. Invited speaker, National Institute for Occupational Safety and Health Seminar, CDC, Morgantown, WV; August 22, 2007
57. “Inflammatory architects of metastatic hepatocellular carcinoma”. Invited speaker, Annual symposium of the NCI Center of Excellence in Immunology, Bethesda, MD, October, 2007
58. “Diagnostic and prognostic signatures of liver cancer”. Co-organizer and speaker, Keystone Symposia on GI cancer, Beijing, China, October 2007
59. “Hepatocellular carcinoma: a genomic perspective”. Invited speaker, UMMS Immunobiology and Transplantation Biology Research Conference, November, 2007
60. “Liver cancer heterogeneity, cellular origin and cancer stem cells”. Invited speaker, NIAAA, DICBR, Rockville, MD, March 2008
61. “What makes liver cancer so deadly” in New Concepts in Organ-Site Research. Invited speaker, The 97th Annual Meeting of the American Association for Cancer Research, San Diego, CA, April 2008
62. “Genomic perspectives of liver cancer”. NCI CCR Grand Rounds speaker, May 2009
63. “Liver Cancer: biology and clinical practice”. Invited speaker, Chulabhorn Research Institute, Thailand, June 2008
64. “Regulation of hepatic cancer stem cells”. Invited speaker, Sino-US Joint Symposium, International Liver Congress, June 2008
65. “Inflammation and liver cancer”. Invited speaker, 2008 International Liver Congress, June 2008.
66. “Genomic perspectives of liver cancer”. Keynote speaker, Chinese Medical Association Annual Meeting, Taipei, June 2008.
67. “Liver cancer heterogeneity and cancer stem cells”. Invited speaker, Institute of Clinical Medicine, National Yang-Ming University School of Medicine Taipei, Taiwan, June 2008.
68. Department of GI Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, July 2008.
69. “The origin of liver cancer”. Invited speaker, 5th ISGC Conference, Oxford, England, Sept 2008.
70. “The role of microRNAs in human hepatocellular carcinoma”. Invited speaker, The NIH Research Festival, October, 2008.
71. “Chronic inflammation and hepatocellular carcinoma”. Invited speaker, Liver and colorectal cancer: molecular biology and clinical research CIBERebd, Barcelona, February 2008
72. “Genome-based molecular predictors of human hepatocellular carcinoma”. Invited speaker, Symposium on Frontiers in Liver Cancer Prevention, Diagnosis, Prognosis and Treatment, Bangkok, Thailand, February 2009
73. “Molecular profiling-insights into the pathogenesis of HCC” in New Concepts in Organ-Site Research. Invited speaker, The 98th Annual Meeting of the American Association for Cancer Research, Denver, CO, April 2009
74. “Role of microRNA in hepatocellular cancer”. ILCA/AACR joint symposium, AACR annual meeting. Denver, CO, April, 2009.

75. “microRNAs in hepatocellular cancer”. Invited speaker, The NCI Cancer and Inflammation Program Retreat. Gettysburg, PA, May 2009
76. “Molecular Diagnosis and Prognosis of Hepatocellular Carcinoma”. Speaker and Organizer; The Second International Workshop on Primary Liver Cancer, Potomac, MD, October, 2009
77. “The art of diagnosis, prognosis and therapeutics in hepatocellular carcinoma”. Invited speaker, The Fifth Annual Symposium on Translational Research: Advances and Challenges in Personalized Healthcare. University of Maryland, Baltimore, MD, October 2009
78. “A genomic interrogation of liver cancer: what genomics can teach us about biology”. Invited speaker, Greehey Children’s Cancer Research Institute Seminar Series, UTHSCSA, San Antonio, TX, November 2009
79. “Hepatocellular carcinoma early detection and its therapeutic implication”. Invited speaker, Workshop on HCC Biomarkers sponsored by CBRG/DCP, Rockville, MD, November 2009
80. “Clinical and molecular stratification of liver cancer”. Invited speaker; Symposium on rare cancers with high mortality: challenges for cancer prevention and treatment, Bethesda, MD, December 2009
81. “Exploration of liver cancer biological space via genome-phenotype-coupled knowledgebase”. Invited speaker; The 40th anniversary celebration of Fudan University Liver Cancer Institute, Shanghai, December 2009.
82. “Exploring liver cancer biological space via genome-phenotype-coupled knowledgebase”. Invited speaker; Molecular medicine Tri-Conference 2010, San Francisco, CA, Feb 2010.
83. “Exploring Liver Cancer Biological Space Via Genome-Phenotype-Coupled Knowledgebase”. Invited speaker, The 1st National Liver Cancer Forum for Middle-aged and Young Experts, Shanghai, March 2010
84. “MicroRNA: Targets For Therapies And Markers For HCC Outcome Prediction”. Invited speaker, The International Liver Congress 2010, Vienna, Austria, April, 2010
85. “Cancer stem cells and liver cancer”. Invited speaker, SCBA-CBA Joint symposium, 15th Annual Conference of CBA, Rockville, MD, June, 2010
86. “microRNA and hepatocellular carcinoma: biology and prognostic significance”. Invited speaker to deliver a special lecture, Fourth ILCA Annual Conference, Montreal, Canada, September, 2010
87. “Cancer stem cells and liver cancer”. Invited speaker, The first JSGE International Topic conference, Kamakura City, Japan, September, 2010
88. “Molecular Profiling - Insights into the Pathogenesis of Liver Cancer”. Invited speaker, the Laboratory of Cell Biology Seminar, CCR, NCI, Bethesda, October, 2010
89. “Integrative Genomics- Insights into the Molecular Pathogenesis of Liver Cancer”. Invited speaker; The Third Thailand-US Workshop on TIGER-LC, Bangkok, November, 2010

2011 – 2015

90. “Building a Personalized Liver Cancer Care and Research Center, (PLCCRC): Rationale & Strategy”. Invited Speaker; The PLCCRC planning meeting. Shanghai, January 2011

91. “MicroRNA and Hepatocellular Carcinoma: Biology and Prognostic Significance”. Invited speaker; Keystone Symposia on microRNAs, non-coding RNAs and cancer. Banff, Alberta, February 2011.
92. “Integrative Analysis of Liver Cancer Omic Data: Linking Genomics and Phenomics to Identify Novel Molecular Targets”. Invited speaker; The 3rd JCA-AACR Special Joint Conference: The Latest Advances in Liver Cancer Research: From Basic Sciences to Therapeutics. Tokyo, Japan, March 2011
93. “Integrative genomics-insights into the molecular pathogenesis of liver cancer”. Invited lecture; The Laboratory of Molecular Biology Seminar, CCR, NCI, Bethesda, March 2011
94. “Liver cancer heterogeneity, tumor subtypes and cancer stem cells”. Invited speaker; AASLD Basic Research Single Topic Conference: Stem Cells in Liver Diseases and Cancer: Discovery & Promise. Atlanta, Georgia, March 2011
95. “Defining Liver Cancer Heterogeneity, Tumor Subtypes and Stem-like HCC”. Invited speaker; Twenty-Sixth Aspen Cancer Conference, Aspen, Colorado, July, 2011
96. “General Session 1: Pathways and Gene Expression Profiles”. Co-Chair; the ILCA 2011 Annual Conference, Hong Kong, September 2011
97. “Defining Liver Cancer Heterogeneity, Tumor Subtypes and Stem-like HCC”. Invited lecture; the 2011 RGC General Research Fund Workshop, Centre for Cancer Research, Li Ka Shing Faculty of Medicine, University of Hong Kong, September 2011
98. “Genome-based predictors of outcome in hepatocellular carcinoma”. Invited lecture; The Liver Meeting 2011, San Francisco, November 2011
99. “Integrative genomics – insights into the molecular pathogenesis of liver cancer”. Invited speaker and co-organizer; The SCBA-NIAAA Joint Symposium on Bioscience, Bethesda, November 2011
100. “Inflammation and liver cancer”. Invited speaker; The Cancer Redox Biology Faculty Symposia, Bethesda, March 2012
101. “microRNA and HCC: Pathogenesis and Prognostic Implications”. Invited speaker; EASL & ILCA Joint Workshop, The International Liver Congress 2012, Barcelona, April, 2012
102. “Targeting Liver Cancer Stem Cells”. Invited speaker; The International Liver Congress 2012, Barcelona, April, 2012
103. “Integrative genomics – insights into tumor heterogeneity and molecular pathogenesis of liver cancer”. Grand Rounds Speaker; Chang Gung Memorial Hospital, Taoyuan, Taiwan, May 2012
104. “Integrative genomics – insights into tumor heterogeneity and molecular pathogenesis of liver cancer”. Keynote Speaker; The 2012 International Symposium on Clinical and Translational Cancer Research, Kaohsiung, Taiwan, May 2012
105. “Biological and clinical implications of the cancer stem cell model in primary liver cancer”. Invited speaker; Cold Spring Harbor Asia Conference on Liver Metabolism, Disorders and Cancer, Suzhou, China, May 2012
106. “Genetic alterations and stem cell progenitors in cholangiocarcinoma”. Invited speaker; CanLiv The Hepatobiliary Cancers Foundation 2nd Annual Symposium, Alexandria, VA, June 2012

107. "Molecular definition of HCC metastasation". Plenary speaker; International HCC conference Heidelberg, June 2012
108. "Integrative Genomics - Insights into Tumor Heterogeneity and Molecular Pathogenesis of Liver Cancer". Plenary speaker; The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting, Shanghai, China, July 2012
109. "Integrated genomics to identify molecular drivers in liver cancer". Plenary speaker; ILCA 6th Annual Conference, Berlin, Germany, September 2012
110. "Genomics of liver cancer". Plenary speaker; AASLD Annual Conference, Boston, November 2012
111. "Deciphering Liver Cancer Heterogeneity: Biological Challenges and Clinical Perspectives". Hou Pao-Chang Memorial Lecturer; Hong Kong Pathology Forum 2013, Hong Kong, January 2013
112. "Translating Molecular Genetics to Clinical Care of HCC". Invited speaker; APASL Liver Week: Clinical Track-HCC, Singapore, June 2013
113. "HCC Management in the Era of Molecular Medicine". Invited speaker; APASL Liver Week, State-of-the-Art Lecture, Singapore, June 2013
114. "Cancer Stem Cells in the Development of Liver Cancer". Invited speaker; APASL Liver Week: Multi-disciplinary Track, Singapore, June 2013
115. "Integrative Genomics - Insights into Tumor Heterogeneity and Molecular Pathogenesis of Liver Cancer". Invited speaker; Cancer Science Institute Distinguished Speakers' Series, Singapore, June 2013
116. "Integrative Genomics - Insights into Tumor Heterogeneity and Molecular Pathogenesis of Liver Cancer". Invited speaker; Mid-Atlantic Directors and Staff of Scientific Cores Conference; Frederick, June 2013
117. "Inflammatory Gene and miRNA Expression in Liver Cancer Diagnosis, Prognosis and Therapy". Invited speaker; The CCR Immunology COE Symposium 2013; Bethesda, September 2013
118. "Mechanistic Insights from Functional Genomics Studies of Liver Cancer Metastasis". Keynote speaker; The 2013 International Symposium on Clinical and Translational Cancer Research; Taipei, September 2013
119. "HCC Management in the Era of Molecular Medicine". Keynote speaker; The 22nd Asia Pacific Cancer Conference, Tianjin, China, November 2013
120. "Integrative Functional Genomics: Insights into Tumor Heterogeneity and Molecular Pathogenesis of Liver Cancer". Invited speaker; Chinese Academy of Medical Sciences, Beijing, China, November 2013
121. "Translating Molecular Genetics to Clinical Care of Liver Cancer". Invited speaker; The Georgetown University Ruesch Center Cancer Symposium, Washington DC, December 2013
122. "Integrated Omics Studies to Delineate Tumor Heterogeneity in Liver Cancer". Plenary speaker; EASL HCC Summit, Geneva, Switzerland, February 2014
123. "Application of functional genomics to explore liver cancer biological space". Invited lecture; Carnegie Institute, Baltimore, MD, February 2014
124. "Molecular profiling of human hepatocarcinogenesis". Invited speaker; EMBO Workshop on Translational Genomics in Biomedicine, Barcelona, March 2014

125. “Integrative Genomics - Insights into Tumor Heterogeneity and Molecular Pathogenesis of Liver Cancer”. Plenary speaker; NCI Third Symposium on Translational Genomics, Bethesda, Maryland, March 2014
126. “Integrative Genomics - Insights into Tumor Heterogeneity and Molecular Pathogenesis of Liver Cancer”. Invited lecture; University of Southern Maine, Portland, Maine, April 2014
127. “Integrative Genomics - Insights into the Molecular Pathogenesis of Liver Cancer”. Invited speaker; Experimental Biology 2014. San Diego, California, April 2014
128. “Translating Molecular Genetics to Clinical Care of Liver Cancer”. Sino-U.S. Forum on Infectious Diseases and Liver Diseases, the 302 Hospital, Beijing, China; June, 2014
129. “Translating Molecular Genetics to Clinical Care of Liver Cancer”. Invited speaker; The 19th CBA Annual Conference. Rockville, MD, June 2014
130. “Integrative Genomics - Insights into Tumor Heterogeneity and Molecular Pathogenesis of Liver Cancer”. Invited speaker; The Mayo Clinic Genomics Interest Group Seminar. Rochester, MN, July, 2014
131. “Biomarker Translational Research in Hepatobiliary Malignancies: The Next 10 Years”. Keynote speaker; The Mayo Clinic Hepatobiliary Cancer Retreat. Rochester, MN, July 2014
132. “Gene Expression Profiles Associated with Progression of HCC”. Plenary speaker; World Transplant Congress. San Francisco, July 2014
133. “Resolving Liver Tumor Heterogeneity through Integrated Systems Biology”. Plenary speaker; the 8th ILCA Annual Conference. Kyoto, Japan, September 2014
134. "Integrated omics studies to delineate tumor heterogeneity in liver cancer". Plenary speaker; International Symposium on Tumor Biology. Kanazawa, Japan, November 2014
135. "Integrative genomics - insights into tumor heterogeneity and molecular pathogenesis of liver cancer". Invited lecture; The Cancer Biology Program Seminar, University of Hawaii Cancer Center, Honolulu, Hawaii, November 2014
136. "The biological and clinical challenges of liver cancer heterogeneity". Invited lecture; UC San Diego Seminar, San Diego, CA, December 2014
137. “The biological and clinical challenges of liver cancer heterogeneity”. Invited speaker; Global Liver Cancer Conference, Honolulu, HI, May 2015
138. “The biological and clinical challenge of liver cancer heterogeneity”. Invited lecture; Medical School of Nantong University, Nantong, China, June 2015
139. “Integrated Omics Investigation of Tumor Heterogeneity and Drivers in Liver Cancer”. Invited lecture; Beijing Proteome Research Center, Beijing, China, June 2015
140. “Immune phenotype of hepatocellular carcinoma and clinical outcome”. Plenary speaker; ILCA Pre-Conference Workshop on Immunopathogenesis and immunotherapy in HCC. Paris, France, September 2015
141. “Precision models clinically relevant to human liver cancer”. Plenary speaker; ILCA Annual Conference, Paris, France, September 2015
142. “Biological and clinical challenges of liver cancer heterogeneity”. Invited speaker; US-Mongolia Workshop

on chronic viral hepatitis and primary liver cancer, Ulaanbaatar, Mongolia, September 2015

143. “The Biological and Clinical Challenge of Liver Cancer Heterogeneity”. Invited lecture; University of Florida Department of Pathology Grand Rounds, Gainesville, FL, October 2015
144. “Integrative Genomics – Insights into Tumor Heterogeneity and Molecular Pathogenesis of Liver Cancer”. Keynote speaker; The 5th International Symposium on Infectious Disease and Signal Transduction. Tainan-Taiwan, November 2015
145. “The Biological and Clinical Challenge of Liver Cancer Heterogeneity”. Invited lecture; Department of Microbiology and Immunology, Drexel University of Medicine, Philadelphia, PA, December 2015

2016 – 2020

146. “Biological and clinical challenges of liver cancer heterogeneity”. Invited lecture; Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, February 2016
147. “Hepatocarcinogenesis and cancer genomic heterogeneity”. Invited speaker; Fourth Symposium on Translational Genomics. NIH, March 2016
148. “The biological and clinical challenge of liver cancer heterogeneity”. Invited lecture; Huashan Hospital, Shanghai, China, April 2016
149. “Hepatocarcinogenesis and cancer genomic heterogeneity”. Invited lecture; Life Sciences Institute, Zhejiang University, Hangzhou, China, April 2016
150. “Integrated Omics Investigation of Tumor Heterogeneity and Drivers in Liver Cancer”. Invited speaker; Cold Spring Harbor Asia conference on Liver Diseases and Tumorigenesis, Suzhou, China, April 2016
151. “Liver cancer genomics and biology”. Invited speaker; NIH CSSA Symposium, NIH, June 2016
152. “Viral hepatitis and hepatocarcinogenesis”. Plenary speaker; The Asian Pacific Association for the Study of the Liver (APASL) Single Topic Conference on Hepatitis C. Kaohsiung, Taiwan, June 2016
153. “Orchestrating HCC development by diverse liver cancer stem cells”. Invited speaker; The 7th Asia-Pacific Primary Liver Cancer Expert Meeting. Hong Kong, July 2016
154. “Cancer heterogeneity and hepatocarcinogenesis”. Invited lecture; Faculty of Health Sciences, University of Macau. Macau, China, July 2016
155. “The importance and relevance of pre-clinical models for human HCC”. Invited speaker; 10th Annual Conference of International Liver Cancer Association. Vancouver, Canada, September 2016
156. “Single cell genome in liver cancer”. Invited speaker; SIG Workshop, 10th Annual Conference of International Liver Cancer Association. Vancouver, Canada, September 2016
157. “Molecular classification of HCC”. Plenary speaker; The 12th Japan Society of Hepatology Single Topic Conference. Kanazawa, Japan, September 2016
158. “Cancer heterogeneity and hepatocarcinogenesis”. Invited speaker; CCR RGC GRF Brainstorming Workshop. Hong Kong, September 2016
159. “Cancer genomic heterogeneity and hepatocarcinogenesis”. Plenary speaker; The 8th Princess Chulabhorn

International Science Congress (PC VIII). Bangkok, Thailand, November 2016

160. “The microenvironment and its contribution to outcome in HCC”. Plenary speaker; EASL HCC Summit. Geneva, Switzerland, February, 2017
161. “The liver cancer puzzle – challenges and opportunities”. Invited speaker; CSSA sponsored lecture series on cancer and treatment. Rockville, Maryland, February, 2017
162. “Cancer genomic heterogeneity and hepatocarcinogenesis”. Invited speaker; The 26th conference of Asian Pacific Association for the Study of the Liver. Shanghai, China, February 2017
163. “Oncogenic drivers and signaling pathways in HCC”. Invited speaker; The 26th conference of Asian Pacific Association for the Study of the Liver. Shanghai, China, February 2017
164. “Liver cancer research and management in the era of precision medicine”. Invited lecture; Shandong Cancer Hospital. Jinan, China, February 2017
165. “Liver cancer genomics and biology”. Invited lecture; Physical Science in Oncology Center Seminar. University of Pennsylvania, Philadelphia, March 2017
166. “Liver cancer genomics and biology”. Invited speaker; the 16th International Symposium of the Society of Chinese Bioscientists in America, Hangzhou, China, June 2017
167. “Cancer genomic heterogeneity and hepatocarcinogenesis”. Invited lecture; Ajou University School of Medicine, Seoul, South Korea, September 2017
168. “Molecular classification and key drivers of intrahepatic cholangiocarcinoma”. Invited speaker; SIG Workshop, 11th Annual Conference of International Liver Cancer Association, Seoul South Korea, September 2017
169. “Cancer genomic heterogeneity and hepatocarcinogenesis”. Invited lecture; Functional RNomics Research Center, Catholic University of Korea, Seoul, South Korea, September 2017
170. “Integrated genomics to uncover clinically relevant HCC driver genes”. Invited speaker; 2017 Seoul Liver Symposium, Seoul National University Hospital, September 2017
171. “The liver cancer puzzle: challenges and opportunities”. Invited lecture; University of Texas Health San Antonio Cell Systems & Anatomy, San Antonio, TX, October 2017
172. “The liver cancer puzzle: challenges and opportunities”. Invited lecture; Tianjin Medical University Cancer Institute and Hospital, November 2017
173. “Biological and clinical impacts of intertumor and intratumor heterogeneity in liver cancer”. Invited speaker; Cold Spring Harbor Asia conference on liver biology, diseases & cancer, Suzhou, China, December 2017
174. “Biological and clinical impacts of intertumor and intratumor heterogeneity in liver cancer”. Invited speaker; Conference on hepatobiliary cancers: pathobiology and translational advances, Glen Allen, Virginia, December 2017
175. “Integrated genomics to identify drivers of human liver cancers”. Plenary speaker; USJCMSP 20th International Conference on Emerging Infectious Diseases in the Pacific Rim, Shenzhen, China, January 2018
176. “Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma. Invited

speaker; USJCMSP 20th International Conference on Emerging Infectious Diseases in the Pacific Rim: Cancer Panel Meeting, Shenzhen, China, January 2018

177. “Biological and clinical impacts of intertumor and intratumor heterogeneity in liver cancer”. Invited lecture; Eastern Hepatobiliary Surgery Hospital, Shanghai, China, January 2018
178. “Biological and clinical impacts of intertumor and intratumor heterogeneity in liver cancer”. Invited speaker; NCI Single Cell Symposium, Bethesda, April 2018
179. “Genomic and biological characterization of primary liver cancer”. Invited speaker; Cancer Signaling Symposium, Loyala University Chicago, April 2018
180. “Genomic and biological characterization of primary liver cancer”. Invited speaker; Ellis Fischel Cancer Center Grand Rounds, University of Missouri School of Medicine, May 2018
181. “Biological and clinical impacts of molecular heterogeneity in liver cancer. Invited lecture; CCR Thoracic and Oncologic Surgery Branch Seminar, July 2018
182. “The dilemmas of cancer genomic heterogeneity”. Keynote speaker; Asan Cancer Institute Symposium, Seoul, Korea, September 2018
183. “Genomic and biological characterization of liver cancer”. Invited speaker; Asan Cancer Institute Symposium, Seoul, Korea, September 2018
184. “Integrated genomics to uncover clinically relevant liver cancer drivers”. Invited speaker; International Symposium on Clinical and Translational Medicine. Shanghai, China, September 2018
185. “Biological and clinical impacts of molecular heterogeneity of liver cancer”. Invited lecture; Indiana University School of Medicine Seminar. September 2018
186. “The dilemmas of liver cancer genomic heterogeneity”. Invited speaker; Commemorative conference of 60th anniversary of cancer hospital, CAMS, the 6th academic conference of national cancer center. Beijing, China, October 2018
187. “Precision oncology in liver cancer”. Plenary speaker; Beijing Liver Cancer International Conference. Beijing, China, November 2018
188. “A TIGER-LC report to Professor Dr. HRH Princess Chulabhorn Mahidol”. Invited speaker; CRI Cancer Symposium 2019; Bangkok, Thailand, January 2019
189. “Precision oncology in liver cancer”. Plenary speaker; CRI Cancer Symposium 2019; Bangkok, Thailand, January 2019
190. “The dilemmas of liver cancer genomic heterogeneity”. Invited lecture; National Yang-Ming University, Taipei, Taiwan, January 2019
191. “Novel approaches to precision medicine in liver cancer”. Plenary speaker; EASL HCC Summit, Lisbon, Portugal, February 2019
192. “Integrated Omics to Define Molecular Heterogeneity in Liver Cancer”. Invited speaker; 24th CBA Annual Conference, Guangzhou, China, June 2019
193. “Integrated Omics to Define Molecular Heterogeneity in Liver Cancer”. Invited speaker; Sun Yat-Sen

University School of Life Sciences Symposium, Guangzhou, China, June 2019

194. “Liver cancer genomics”. Plenary speaker; the 8th International Oda Memorial Symposium, Tokyo, Japan, August 2019
195. “Are we winning the war on cancer? Landscape of tumor cell communities and their impact on immunotherapy in liver cancer”. Plenary speaker; The 10th Asia-Pacific Primary Liver Cancer Expert Meeting, Sapporo, Japan, August 2019
196. “Race-related liver tumor subtypes are associated with gut microbiome-mediated metabolism”. Plenary speaker; The 12th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved. San Francisco, CA, September 2019
197. “Landscape of tumor cell communities and their impact on immunotherapy in liver cancer”. Invited speaker; DBSTP seminar, St Jude Children’s Research Hospital, Memphis, TN, November 2019
198. “Molecular landscape of tumor ecosystem in liver cancer”. Keynote speaker; 17th National Liver Cancer Conference. Shanghai, China, December 2019
199. “The landscape of tumor cell communities and its impact on therapy in liver cancer”. Plenary speaker; TASL 2019 Annual Meeting and the st TASL-AASLD Joint Symposium Theme: Trends in the Management of Liver Diseases in the 2020s. Taipei, Taiwan, December 2019
200. “The landscape of tumor molecular heterogeneity in liver cancer”. Invited lecture; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, December 2019
201. “Precision medicine – from liquid biopsy to artificial intelligence”. Plenary speaker; Workshop on primary liver cancer – emerging concepts and novel treatments, the 2020 GASL, Mainz, Germany, February 2020
202. “Are we winning the war on cancer? Reflections on years of research in liver cancer genomics”. Invited speaker; CALS monthly virtual seminar series, July 2, 2020
203. “Are we winning the war on cancer? Reflections on years of research in liver cancer genomics”. Invited speaker; ACACR monthly virtual seminar series, August 14, 2020
204. “Are we winning the war on cancer? Reflections on years of research in liver cancer genomics”. Invited speaker; NIH-CSSA Virtual Seminar series, October 3, 2020
205. “Challenges in liver cancer diagnosis”. The Virtual NCI Cancer Diagnostics Innovation Workshop, October 8-9, 2020
206. “Are we winning the war on cancer? Challenges and opportunities”. Plenary speaker; The 4th Beijing International Conference on Hepatobiliary Carcinoma and Infectious Diseases. Beijing, China; November 2020
207. “Is there anything in common among liver cancer and COVID-19?” Plenary speaker; The Virtual SCBA DC-Baltimore Chapter Annual Scientific Symposium, December 2020

2021 – 2025

208. “Defining liver cancer heterogeneity – new challenges and opportunities”. NCI CCR Grand Rounds; February 2021

209. “Causes and functional intricacies of intertumor and intratumor heterogeneity in hepatobiliary cancers”. Keystone eSymposia on hepatobiliary cancers; March 2021
210. “Understanding tumor cell functional clonality and its evolution by single-cell transcriptome in liver cancer”. AACR 2021; April & May
211. “Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma”. The 107th Japanese Society of Gastroenterology Annual Conference; April 2021
212. “Immunological characterization of liver cancer”. Invited lecture; NCI CCR Laboratory of Cancer Immunometabolism; April 2021
213. “Cancer stemness and its clinical impact in hepatobiliary cancers”. Co-organizer and speaker; Keystone eSymposia on cancer stem cells: advances in biology and clinical translation; May 2021
214. “Single-cell genomics and response to therapies in liver cancer”. Plenary speaker; the 2021 ILCA Annual Conference; September 2021
215. “Causes and functional intricacies of molecular heterogeneity in liver cancer”. Keynote speaker; the 2021 International HBV Meeting; Toronto, Canada, September 2021
216. “Molecular pathogenesis of liver cancer”. Invited speaker; the CCR-LCBG Seminar; September 2021
217. “Causes and functional intricacies of intertumor and intratumor heterogeneity in liver cancer”. Plenary speaker; San Antonio Liver Cancer Symposium, October 2021
218. “Defining liver cancer molecular heterogeneity – new challenges and opportunities”. Invited speaker; the University of Hong Kong SKLLR virtual Seminar, October 2021
219. “Challenges and opportunities of precision oncology in liver cancer”. Plenary speaker; The 5th International Conference on Hepatobiliary Carcinoma and Infectious Diseases, Virtual attendance, November 2021
220. “State of the art in liver cancer research: prevention and early detection”. Plenary speaker; the 13th AORTIC International Conference on Cancer in Africa, Virtual conference, November 2021
221. “Molecular information from single cell-sequencing”. Meet-the-Expert session speaker; The Liver Meeting 2021, the AASLD Annual Virtual Symposium, November 2021
222. “Spatial single-cell dissection of tumor-immune landscape in liver cancer”. Invited speaker; The CSH-Asia Hybrid meeting on Liver Development, Metabolism, Disease & Cancer. December 2021
223. “Functional Genomics of liver cancer: dissecting molecular heterogeneity to improve early detection, mechanistic understanding of hepatocarcinogenesis and therapeutic efficacy”. Invited lecture, University of Southern California Spring Lecture. February 2022
224. “Microenvironment reprogramming in HCC”. Invited speaker; Experimental Biology 2022. Philadelphia, PA, April 2022.
225. “Molecular landscapes of hepatocellular carcinoma and cholangiocarcinoma”. Plenary speaker; the AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer. Boston, MA, May 2022.
226. “A genetic basis of nonalcoholic steatohepatitis (NASH)-related HCC”. Invited speaker; FASEB Liver

Biology Conference: Fundamental Mechanisms and Translational Applications, New Orleans, LA, June 2022

227. “Pan-viral serological repertoires linked to liver cancer risk”. Invited speaker; EASL International Liver Congress, London, UK, June 2022
228. “Molecular landscapes of liver cancer”. Invited lecture; MoE Frontiers Science Center for Precision Oncology Seminar Series, University of Macau, Faculty of Health Science, July 12, 2022.
229. “Risk prediction and early detection of liver cancer”. Invited speaker; Africa HepatoPancreatoBiliary Cancer Consortium 2022: transforming HepatoPancreatoBiliary cancer research and care in the omics era. Cairo, Egypt, August 2022.
230. “Molecular landscapes of liver cancer”. Invited speaker; Houston Methodist Neal Cancer Center Seminar, January 2023.
231. “Molecular landscapes of liver cancer”. Invited speaker; TIGER-LC consortium symposium, a report to Her Royal Highness Princess Dr. Chulaborn. Bangkok, January 2023
232. “Development and validation of cancer biomarker”. Young Investigators Workshop at the APASL-AASLD joint symposium. Taipei, Taiwan, February 2023
233. “Evolution of cell composition during hepatocellular carcinoma progression and treatment”. Invited speaker; APASL Annual Meeting 2023. Taipei, Taiwan, February 2023
234. “The potential of spatial transcriptomics in liver cancer”. Invited speaker, the 10th Cholangiocarcinoma Foundation Annual Conference. Salt Lake City, April 2023
235. “Molecular landscapes of liver cancer”. Invited speaker; Feinstein Institutes for Medical Research, Northwell Heal/CSHL Cancer Seminar Series. New York, May 2023
236. “Molecular landscape of liver cancer and its clinical implications”. Invited speaker, Frontiers in Oncology Seminar, University of Maryland, School of Medicine, Baltimore, June 2023
237. “Molecular landscape of liver cancer and its clinical implications”. Invited speaker, Laboratory of Cancer Biology and Genetics seminar series, CCR, NCI, June 2023
238. “Molecular landscape of liver cancer and its implications for precision medicine”. Invited speaker, Ajou University School of Medicine lecture series, Suwon, Korea, July 2023
239. “Molecular landscape of liver cancer and its implications for precision medicine”. Invited speaker, The 13th Asia-Pacific Primary Liver Cancer Expert Meeting, Seoul, Korea, July 2023
240. “Molecular landscape of liver cancer and its implications for precision medicine”. Keynote speaker, 2023 CALS Symposium, Banff, Alberta, August 2023
241. “The complexity of inter- and intratumoral heterogeneity: insights from single cell technology”. Invited speaker, 2023 FASEB Cholangiocarcinoma conference, Palm Springs, CA, August 2023
242. “Spatial proteomics of liver cancer”. Plenary speaker; the 2023 ILCA Annual Conference, Amsterdam, Netherlands, September 2023
243. “Exploring challenges and opportunities in early detection and risk prediction of liver cancer”. Keynote speaker, Early Cancer Institute Annual Symposium, University of Cambridge, September 2023

244. “Why is it so difficult to study/understand liver cancer? – challenges and solutions in overcoming cancer heterogeneity”. Invited speaker, NCI CCR Laboratory of Cell Biology Seminar Series, Bethesda, Maryland, September 2023
245. “Molecular landscape of liver cancer and its clinical implications”. NCI Research Highlights Presentations. Frederick, Maryland, October 2023
246. “A genetic basis of NASH (MASH)-related HCC”. Plenary speaker, San Antonio Liver Cancer Symposium. San Antonio, TX, October 2023
247. “Dissecting molecular heterogeneity to improve early detection, mechanistic understanding of hepatocarcinogenesis and therapeutic efficacy”. Invited speaker, NCI CCR Laboratory of Molecular Biology Seminar Series, Bethesda, Maryland, October 2023
248. “A global view of early detection of liver cancer”. Invited speaker, UICC-World Hepatitis Alliance session, AORTIC 2023, Dakar, Senegal, Nov 2023
249. “Multidisciplinary research network to improve early detection, diagnosis, prognosis and treatment of liver cancer: opportunities for personalized therapy”. Invited speaker, AORTIC 2023, Dakar, Senegal, Nov 2023
250. “Cracking the code: molecular features of liver cancer”. Invited speaker, the 2023 NIH AANHPI Distinguished Scholar Lecture, December 2023
251. “A global view of early detection of liver cancer”. Gastrointestinal & Hepatobiliary Cancer Symposium, Shanghai, China, February 2024
252. “Molecular landscape of liver cancer and its clinical implications”. USJCMSP Hepatitis Panel Symposium, Seoul, South Korea, March 2024
253. “Molecular landscape of liver cancer and its clinical implications”. Pittsburgh Liver Research Center Seminar series. Pittsburgh, PA, March 2024

Bibliography

ORCID: <http://orcid.org/0000-0001-9735-606X>.

Scopus; Web of Science ResearcherID (Thomson Reuters): B-6162-2009.

258 articles with citation data, 26,409 citations, H-Index: 87 (4/2024)

Articles in Peer-Reviewed Journals (in reverse chronological order)

1. Pupacdi B, Loffredo CA, Budhu A, Rabibhadana S, Bhudhisawasdi V, Pairojkul C, Sukeepaisalkul W, Pugkhem A, Luvira V, Lertprasertsuke N, Chitirosnirarnit A, Auewarakul CU, Ungtrakul T, Sricharunrat T, Sangrajrang S, Phornphutkul K, Albert P, Kim SD, Harris CC, Mahidol C, **Wang XW**, Ruchirawat M. The landscape of etiological patterns of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in Thailand. *Int J Cancer* 2024. PMID:
2. Fu Y, Maccioni L, **Wang XW**, Greten TF, Gao B. Alcohol-associated liver cancer. *Hepatology* 2024. (Review) PMID: 38607725
3. Kacar Z, Slud E, Levy D, Candia J, Budhu A, Forgues M, Wu X, Raziuddin A, Tran B, Shetty J, Pomyen Y, Chaisaingmongkol J, Rabibhadana S, Pupacdi B, Bhudhisawasdi V, Lertprasertsuke N, Auewarakul C, Sangrajrang S, Mahidol C, Ruchirawat M, **Wang XW**. Characterization of tumor evolution by functional clonality and phylogenetics in hepatocellular carcinoma. *Commun Biol* 7: 383, 2024. PMID: 38553628
4. Wang L, Revsine M, **Wang XW**, Ma L. Single-cell characterization of the tumor ecosystem in liver cancer. *Methods Mol Biol.* 2769: 153-66, 2024. PMID: 38315396
5. Chen L, Zhang C, Xue R, Liu M, Bai J, Bao J, Wang Y, Jiang N, Li Z, Wang W, Wang R, Zheng B, Yang An, Hu J, Liu K, Shen S, Zhang Y, Bai M, Wang Y, Zhu Y, Yang S, Gao Q, Gu J, Gao D, **Wang XW**, Nakagawa H, Zhang N, Wu L, Rozen SG, Bai F and Wang HY. Deep whole-genome analysis of 494 hepatocellular carcinoma. *Nature* 627: 586-93, 2024. PMID: 38355797
6. Chang CW, Chen YS, Huang CH, Lin CH, Ng WV, Chu LJ, Trepo E, Zucman-Rossi J, Siao K, Maher JJ, Chiew MY, Chou CH, Huang HD, Teo WH, Lee IS, Lo JF, **Wang XW**. A genetic basis of mitochondrial DNAJA3 in nonalcoholic steatohepatitis-related hepatocellular carcinoma. *Hepatology* 2024. PMID: 37870291
7. Revsine M, Wang L, Forgues M, Behrens S, Craig AJ, Liu M, Tran B, Kelly M, Budhu A, Monge C, Xie C, Hernandez JM, Greten TF, **Wang XW**, Ma L. Lineage and ecology define liver tumor evolution in response to treatment. *Cell Rep Med* 5: 101394, 2024. PMID: 38280378
8. Green BL, Myojin Y, Ma C, Ruf B, Ma L, Zhang Q, Rosato U, Qi J, Revsine M, Wabitsch S, Bauer K, Benmebarek MR, McCallen J, Nur A, Wang X, Sehra V, Gupta R, Claassen M, **Wang XW**, Korangy F, Greten TF. Immunosuppressive CD29⁺ Treg accumulation in the liver in mice on checkpoint inhibitor therapy. *Gut* 73: 509-20, 2024. PMID: 37770128
9. Maestri E, Kedei N, Khatib S, Forgues M, Ylaya K, Hewitt SM, Wang L, Chaisaingmongkol J, Ruchirawat M, Ma L, **Wang XW**. Spatial proximity of tumor-immune interactions predicts patient outcome in hepatocellular carcinoma. *Hepatology* 79: 768-79, 2024. PMID: 37725716
10. Monge C, Xie C, Myojin Y, Coffman K, Mabry-Hrones D, Wang S, Budhu A, Figg WD, Cam M, Fennely R, Levy EB, Kleiner DE, Steinberg SM, **Wang XW**, Redd B, Wood BJ, Greten TF. Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary track carcinoma. *Cancer Med* 13: e6912, 2024. PMID: 38205877

11. Do WL, Wang L, Forgues M, Liu J, Rabibhadana S, Pupacdi B, Zhao Y, Gholian H, Bhudhisawasdi V, Pairojkul C, Sukeepaisalkul W, Pugkhem A, Luvira V, Lertprasertsuke N, Chotirosniramit A, Auewarakul CU, Ungtrakul T, Sricharunrat T, Sangrajrang S, Phornphutkul K, Budhu A, Harris CC, Mahidol C, Ruchirawat M, **Wang XW**. Pan-viral serology uncovers distinct virome patterns among hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *Cell Rep Med* 4: 101328, 2023. PMID: 38118412
12. Huth T, Dreher EC, Lemke S, Fritzsche S, Sugiyanto RN, Castven D, Ibberson D, Sticht C, Eiteneuer E, Jauch A, Pusch S, Albrecht T, Goepfert B, Candia J, **Wang XW**, Ji J, Marquardt JU, Nahnsen S, Schirmacher P, Roessler S. Chromosome 8p-engineering reveals increased metastatic potential targetable by patient-specific synthetic lethality in liver cancer. *Science Adv* 9: eadh1442, 2023. PMID: 38134284
13. Craig AJ, Silveira MAD, Ma L, Revsine M, Wang L, Heinrich S, Rae Z, Ruchinkas A, Dadkhah K, Do W, Behrens S, Mehrabadi FR, Dominguez DA, Forgues M, Budhu A, Chaisaingmongkol J, Hernandez JM, Davis JL, Tran B, Marquardt JU, Ruchirawat M, Kelly M, Greten TF, **Wang XW**. Genome-wide profiling of transcription factor activity in primary liver cancer using single cell ATAC sequencing. *Cell Rep* 42: 113446, 2023. PMID: 37980571
14. Panigrahi G, Candia J, Dorsey TH, Tang W, Ohara Y, Byun JS, Minas TZ, Zhang AL, Ajao A, Cellini A, Cellini A, Yfantis HG, Mann D, Loffe O, **Wang XW**, Liu H, Loffredo CA, Napoles A, Ambs S. Diabetes-associated breast cancer is molecularly distinct and shows a DNA damage repair deficiency. *JCI Insight* e170105, 2023. PMID: 37906280
15. Hung MH and **Wang XW**. Targeting WNT/ β -catenin via modulating EZH2 function – a new chapter in the treatment of β -catenin mutant hepatocellular carcinoma? *Cancer Res* 83: 3498-500, 2023. (review) PMID: 37747420
16. Greten TF, Villanueva A, Korangy F, Ruf B, Yarchoan M, Ma L, Ruppin E, **Wang XW**. Biomarkers for immunotherapy of hepatocellular carcinoma. *Nat Rev Clin Oncol* 20: 780-98, 2023. (review) PMID: 37726418
17. Pomyen Y, Chaisaingmongkol J, Rabibhaddna S, Pupacdi B, Sripan D, Chornkrathok C, Budhu A, Bhudhisawasdi V, Lertprasertsuke N, Chotirosniramit A, Pairojkul C, Auewarakul CU, Ungtrakul T, Sricharunrat T, Phonphutkul K, Sangrajrang S, Loffredo CA, Harris CC, Mahidol C, **Wang XW**, Ruchirawat, & TIGER-LC Consortium. Gut Dysbiosis in Thai intrahepatic cholangiocarcinoma and hepatocellular carcinoma. *Sci Rep* 13: 11406, 2023. PMID: 37452065
18. Feng D, Xiang X, Guan Y, Guillot A, Lu HJ, Chang C, He Y, Wang H, Pan H, Ju C, Colgan S, Tacke F, **Wang XW**, Kunos G, Gao B. Monocyte-derived macrophages orchestrate multiple cell-type interactions to repair necrotic liver lesions in disease models. *J Clin Invest* 133: e166954, 2023. PMID: 37338984
19. Ruf B, Bruhns M, Babaei S, Kedei N, Ma L, Revsine M, Benmebarek MR, Ma C, Heinrich B, Subramanyam V, Qi J, Wabitsch S, Green BL, Bauer KC, Myojin Y, Greten LT, McCallen JD, Huang P, Trehan R, Wang X, Nur A, Qiang D, Soika M, Pouzolles M, Evans CN, Chari R, Kleiner DE, Telford W, Dadkhah K, Ruchinkas A, Stovroff MK, Kang J, Oza M, Ruchirawat M, Kroemer A, **Wang XW**, Claassen M, Korangy F, Greten TF. CSF1R⁺PD-L1⁺ Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin. *Cell* 186: 3686-705.e32, 2023. PMID: 37595566
20. Budhu A, Pehrsson EC, He A, Goyal L, Kelley RK, Dang H, Xie C, Monge C, Tandon M, Ma L, Kuhlman L, Zhang K, Baiev I, Kleiner D, Hewitt S, Tran B, Shetty J, Wu X, Zhao Y, Shen TW, Choudan S, Kriga Y, Ylaya K, Warner A, Edmonson E, Forgues M, Greten TF, **Wang XW**. Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy. *Cell Rep Med* 16: 101052,

2023. PMID: 37224815

21. Hung MH, Chang CW, Wang KC, Chaisaingmongkol J, Ruchirawat M, Greten TF, **Wang XW**. Purine anabolism creates therapeutic vulnerability in hepatocellular carcinoma via m6A-mediated epitranscriptomic regulation. *Hepatology* 78: 1462-77, 2023. PMID: 37094826
22. D'Artista L, Seehawer M, Barozzi I, Craig A, Moschopoulou AA, Henning M, Klotz S, Heinzmann F, Harbig J, Kang TW, Rist E, Herrmann L, Sipos B, Longerich T, Eilers M, **Wang XW**, Zender L. Myc determines lineage commitment in primary liver tumorigenesis. *J Hepatol* 79: 141-9, 2023. PMID: 36906109
23. Wu B, Guan L, Chin L, Dang H, Xu Y, Ren J, Li T, Chen YH, Mills G, Radhakrishnan R, Furth EE, Gimotty PA, **Wang XW**, Wells RG, Guo W. Stiff Matrix Induces Exosome Secretion to Promote Tumor Progression. *Nat Cell Biol* 25: 415-24, 2023. PMID: 36797475
24. Enose-Akahata Y, Wang L, Almsned F, Johnson KR, Mina Y, Ohayon J, **Wang XW**, Jacobson S. The repertoire of CSF anti-viral antibodies in patients with neuroinflammatory diseases. *Sci Adv* 9: eabq6978, 2023. PMID: 36598996
25. Fu Y, Mackowiak B, Feng D, Lu JH, Pan H, **Wang XW**, He Y, Gao B. MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression. *Gut* 72: 1942-58, 2023. PMID: 36593103
26. Greten TF, Schwabe R, Bardeesy N, Ma L, Goyal L, Kelley R, **Wang XW**. Immunology and immunotherapy of cholangiocarcinoma. *Nat Rev Gastroenterol Hepatol* 20: 349-65, 2023. (review) PMID: 36697706
27. Ma L, Heinrich S, Wang L, Mahn F, Khatib S, Forgues M, Kelly M, Hewitt SM, Hernandez JM, Mabry D, Klockner R, Greten TF, Chaisaingmongkol J, Ruchirawat M, Marquardt J, **Wang XW**. Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features of a malignant ecosystem in liver cancer. *Nat Commun* 13: 7533, 2022. PMID: 36476645
28. Behrens S and **Wang XW**. Dissecting Intratumor Heterogeneity in HCC: New Research Strategies & Clinical Implications. *Carcinogenesis* 43, 1103-09, 2022. (review) PMID: 36512331
29. Wang L, Candia J, Ma L, Zhao Y, Imberti L, Sottini A, Quiros-Roldan E, Dobbs K, Burbelo PDCohen JI, Delmonte OM, Forgues M, Liu H, Mathews HF, Shaw E, Stack MA, Weber SE, Zhang Y, Lisco A, Sereti I, Su HC, Notarangelo LD, **Wang XW**. Serological Responses to Human Virome Define Clinical Outcomes of Italian Patients Infected with SARS-CoV-2. *Int J Biol Sci*. 18: 5591-606, 2022. PMID: 36263161
30. Chang CW, Wei Z, Durell SR, Ma L, Forgues M, **Wang XW**. A Compendium of Co-Regulated Mitochondrial Protein Complexes in Pan-Cancer Unravels Collateral Defective Events. *iScience* 25: 105244, 2022. PMID: 36274950
31. Khatib SA and **Wang XW**. Causes and functional intricacies of inter- and intratumor heterogeneity of primary liver cancers. *Adv Cancer Res* 156: 75-102, 2022. (review) PMID: 35961709
32. Parker AL, Toulabi L, Oike T, Kanke Y, Patel D, Tada T, Taylor S, Beck JA, Bowman E, Reyzer ML, Butcher D, Kuhn S, Pauly GT, Krausz KW, Gonzalez FJ, Hussain SP, Ambs S, Ryan BM, **Wang XW**, Harris CC. Creatine riboside is a cancer cell-derived metabolite associated with arginine auxotrophy. *J Clin Invest* 132 (14): e157410, 2022. PMID: 35838048
33. Aghayev T, Mazitova AM, Fang JR, Peshkova IO, Rausch M, Hung MH, White KF, Masia R, Titerina EK, Fatkhullina AR, Cousineau I, Turcotte S, Zhigarev D, Kurilenko N, Marchenko A, Khozyainova S, Makhov P,

- Tan YF, Kossenkov A, Wiest D, Stagg J, **Wang XW**, Campbell KS, Dzutsev A, Trinchien G, Hill JA, Grivennikov SI, Koltsova EK. Interleukin-27 signaling serves as immunological checkpoint for innate cytotoxic cells to promote hepatocellular carcinoma. *Cancer Discov* 12: 1960-83, 2022. PMID: 35723626
34. Li Z, Kwon SM, Li D, Li L, Peng X, Zhang J, Sueyoshi T, Raufman JP, Negishi M, **Wang XW**, Wang H. Human constitutive androstane receptor represses liver cancer development and hepatoma cell proliferation via erythropoietin signaling. *J Biol Chem* 298: 101855. 2022. PMID: 35367211
 35. Wabitsch S, McCallen JD, Kamenyeva O, Ruf B, McVey JC, Kabat J, Walz JS, Rotman Y, Bauer KC, Craig AJ, Pouzolles M, Phadke I, Catania V, Green BL, Fu C, Diggs LP, Heinrich B, **Wang XW**, Ma C, Greten TF. Metformin treatment rescues CD8+ T cell response to immune checkpoint inhibitor therapy in mice with NAFLD. *J Hepatol* 77: 748-60, 2022. PMID: 35378172
 36. Silveira MAD, Bilodeau S, Greten TF, **Wang XW**, Trinchieri G. The gut-liver axis: host-microbiota interactions shape hepatocarcinogenesis. *Trends Cancer* 8: 583-97, 2022. (review) PMID: 35331674
 37. Khatib SA, Ma L, Dang H, Forgues M, Chung JY, Ylaya K, Hewitt SM, Chaisaingmongkol J, Rochirawat M, **Wang XW**. Single-cell biology uncovers apoptotic cell death and its spatial organization as a potential modifier of tumor diversity in hepatocellular carcinoma. *Hepatology* 76: 599-611, 2022. PMID: 35034369
 38. Minas TZ, Candia J, Dorsey TH, Baker F, Tang W, Kiely M, Smith CJ, Zhang A, Jordan SV, Obadi OM, Ajao A, Tetty Y, Biritwum RB, Adjei AA, Mensah JE, Hoover RN, Jenkins FJ, Kittles R, Hsing AW, **Wang XW**, Loffredo CA, Yates C, Cook MB, Ambs S. Serum proteomics links suppression of tumor immunity to ancestry and lethal prostate cancer. *Nat Commun* 13: 1759, 2022. PMID: 35365620
 39. Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves H, **Wang XW**, Gores GJ, Vilanueva A. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. *Nat Cancer* 3: 386-401, 2022. (review) PMID: 35484418 (highly cited paper)
 40. Monge C, Pehrsson EC, Xie C, Duffy AG, Mabry D, Wood BJ, Kleiner D, Steinberg SM, Figg D, Redd B, Budhu A, Wang S, Tandon M, Ma L, **Wang XW**, Greten TF. A phase 2 study of pembrolizumab in combination with capecitabine and oxaliplatin with molecular profiling in patients with advanced biliary tract carcinoma. *The Oncologist* 27: e273-85, 2022. PMID: 35274717
 41. Ma L & **Wang XW**. Dissecting liver tumor heterogeneity to improve health equity. *Trends Cancer* 8: 286-90, 2022. (review) PMID: 35012904
 42. Liu Y, Zhuo S, Zhou Y, Ma L, Sun Z, Wu X, **Wang XW**, Gao B, Yang Y. Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis. *J Hepatol* 76: 652-64, 2022. PMID: 34793870
 43. Wang Z, Budhu A, Shen Y, Wong L, Hernandez BY, Tiirikainen M, Ma X, Irwin ML, Lu L, Zhao HY, Lim JK, Taddei T, Mishra L, Pawlish K, Stroup A, Brown R, Nguyen MH, Koshiol J, Hernandez MO, Forgues M, Yang HI, Lee MH, Huang YH, Iwasaki M, Goto A, Suzuki S, Matsuda K, Tanikawa C, Kamatani Y, Mann D, Guarnera M, Shetty K, Thomas C, Yuan JM, Khor CC, Koh WP, Risch H, **Wang XW**, Yu H. Genetic Susceptibility to Hepatocellular Carcinoma in Chromosome 22q13.31, findings of a genome-wide association study. *JGH Open* 5, 1363-72, 2021. PMID: 34950780
 44. Cable J, Pei D, Reid LM, **Wang XW**, Bhatia S, Karras P, Melenhorst JJ, Grompe M, Lathia JD, Song E, Kuo CJ, Zhang N, White RM, Ma SK, Ma L, Chin YR, Shen MM, Ng IOL, Kaestner KH, Zhou L, Sikandar S, Schmitt CA, Guo W, Wong CCL, Ji J, Tang DG, Dubrovskaya A, Yang C, Wiedemeyer WR and Weissman IL. Cancer stem cells: advances in biology and clinical translation – a Keystone Symposia report. *Ann NY Acad*

Sci doi: 10.1111/nyas.14719, 2021. (Review) PMID: 34850398

45. Schäffer AA, Dominguez DA, Chapman LM, Gertz EM, Budhu A, Forgues M, Chaisaingmongkol J, Rabibhadana S, Pupacdi B, Wu X, Harris CC, Ruchirawat M, Ruppin E, **Wang XW**. Integration of adeno-associated virus (AAV) into the genomes of most Thai and Mongolian liver cancer patients does not induce oncogenesis. *BMC Genomics* 22: 814, 2021. PMID: 34763675
46. Liu N, Chang CW, Steer CJ, Wang XW, Song G. MicroRNA-15a/16-1 Prevents Hepatocellular Carcinoma by Disrupting the Communication between Kupffer Cells and Tregs. *Gastroenterology* 162: 575-89, 2022. PMID: 34678217 (highly cited paper)
47. Heinrich B, Gertz EM, Schäffer A, Craig AJ, Ruf B, Subramanyam V, McVey JC, Diggs LP, Heinrich S, Rosato U, Ma C, Yan C, Hu Y, Zhao Y, Shen TW, Kapoor V, Telford W, Kleiner D, Stovroff MK, Dhani HS, Kang J, Fishbein TM, **Wang XW**, Ruppin E, Kroemer A, Greten TF, and Korangy F. The tumor microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma. *Gut* doi: 10.1136/gutjnl-2021-325288, 2021. PMID: 34340996
48. Ma L, Wang L, Khatib S, Chang CW, Heinrich S, Dominguez D, Forgues M, Candia J, Hernandez MO, Kelly M, Zhao Y, Tran B, Hernandez JM, Davis JL, Kleiner DE, Wood BJ, Greten TF, **Wang XW**. Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *J Hepatol* 75: 1397-1408, 2021. PMID: 34216724 (highly cited paper)
49. Pomyen Y, Budhu A, Chaisaingmongkol J, Forgues M, Dang H, Ruchirawat M, Mahidol C, **Wang XW**, & the TIGER-LC Consortium. Tumor metabolism and associated serum metabolites define prognostic subtypes of Asian hepatocellular carcinoma. *Sci Rep* 11: 12097, 2021. PMID: 34103600
50. Hung MH, Lee JS, Ma C, Diggs LP, Heinrich S, Chang CW, Ma L, Forgues M, Budhu A, Chaisaingmongkol J, Ruchirawat M, Ruppin E, Greten TF, **Wang XW**. Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma. *Nat Commun* 12: 1455, 2021. PMID: 33674593 (highly cited paper)
51. Ma L, Khatib S, Craig AJ, **Wang XW**. Toward a Liver Cell Atlas: Understanding Liver Biology in Health and Disease at Single-cell Resolution. *Semin Liver Dis* 41: 321-30, 2021 (review). PMID: 34130336
52. Zhang Q, Ma C, Duan Y, Heinrich B, Rosato U, Diggs LP, Ma L, Roy S, Fu Q, Brown Z, Wabitsch S, Thovarai V, Fu J, Feng D, Ruf B, Cui L, Subramanyam V, Frank KM, Wang S, Kleiner DE, Ritz T, Rupp C, Gao B, Longerich T, Kroemer A, **Wang XW**, Ruchirawat M, Korangy F, Schnabl B, Trinchieri G, Greten TF. Gut microbiome directs hepatocytes to recruit MDSC and promote cholangiocarcinoma. *Cancer Discov* 11: 1248-67, 2021. PMID: 33323397 (highly cited paper)
53. Diggs LP, Ruf B, Ma C, Heinrich B, Cui L, Zhang Q, McVey JC, Wabitsch S, Heinrich S, Rosato U, Lai W, Subramanyam V, Longerich T, Loosen SH, Luedde T, Meumann UP, Desar S, Kleiner D, Gores GJ, **Wang XW**, Greten TF. CD40-mediated immune cell activation enhances response to anti-PD1 in murine intrahepatic cholangiocarcinoma. *J Hepatol* 74: 1145-54, 2021. PMID: 33276030 (highly cited paper)
54. Wang L, Candia J, Ma L, Zhao Y, Imberti L, Sottini A, Dobbs K, NIAID-NCI COVID Consortium, Lisco A, Sereti I, Su HC, Notarangelo LD, **Wang XW**. Serological Responses to Human Virome Define Clinical Outcomes of Italian Patients Infected with SARS-CoV-2. *medRxiv*. 2020 Sep 7;2020.09.04.20187088. doi: 10.1101/2020.09.04.20187088. Preprint. PMID: 32908997
55. Heinrich S, Craig AJ, Ma L, Heinrich B, Greten TF, **Wang XW**. Understanding of tumor cell community and its response to immunotherapy in liver cancer by single cell analysis. *J Hepatol* 74: 700-15, 2021 (review).

PMID: 33271159

56. Zhao N, Dang H, Ma L, Martin SP, Forgues M, Ylaya K, Hewitt SM, **Wang XW**. Intratumoral gd T-cell infiltrates, CCL4/5 protein expression and survival in patients with hepatocellular carcinoma. *Hepatology* 73: 1045-60, 2021. PMID: 32502310
57. Wei X, Zhao L, Ren R, Ji F, Xue S, Zhang J, Liu Z, Ma Z, **Wang XW**, Wong L, Liu N, Shi J, Guo X, Roessler S, Zheng X, Ji J. MiR-125b Loss Activated HIF1 α /pAKT Loop, Leading to Trans-Arterial Chemoembolization Resistance in Hepatocellular Carcinoma. *Hepatology* 73: 1381-98, 2021. PMID: 32609900
58. Candia J, Bayarsaikhan E, Tandon M, Budhu A, Forgues M, Tovuu LO, Tudev U, Lack J, Chao A, Chimburen J, **Wang XW**. The genomic landscape of Mongolian hepatocellular carcinoma. *Nat Commun* 11: 4383, 2020. PMID: 32873799
59. Gu Y, Ji F, Liu N, Zhao Y, Wei X, Hu S, Jia W, **Wang XW**, Budhu A, Ji J, Zhao B, Roessler S, Zheng X, Ji J. Loss of miR-192-5p initiates a hyperglycolysis and stemness positive feedback in hepatocellular carcinoma. *J Exp Clin Cancer Res*. 39: 268, 2020. PMID: 33256802
60. Høgdall D, O'Rourke CJ, Dehlendorff C, Larsen OF, Jensen LH, Johansen AZ, Dang H, Factor VM, Grunnet M, Mau-Sørensen M, Oliveira DVNP, Linnemann D, Boisen MK, **Wang XW**, Johansen JS, Andersen JB. Serum IL-6 as a prognostic biomarker and IL-6R as a therapeutic target in biliary tract cancers. *Clin Cancer Res* 26: 5655-67, 2020. PMID: 32933994
61. Liu J, Tang W, Budhu A, Forgues M, Hernandez MO, Candia J, Kim Y, Bowman ED, Ambs S, Zhao Y, Tran B, Wu X, Koh C, Surana P, Liang TJ, Guarnera M, Mann D, Rajaure M, Greten TF, Wang Z, Yu H, **Wang XW**. A viral exposure signature defines early onset of hepatocellular carcinoma. *Cell* 182: 317-28, 2020. PMID: 32526205.
62. Martin SP, Fako V, Dang H, Khatib S, Ma L, Dominguez D, Wang H, Zheng W, **Wang XW**. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma. *J Exp Clin Cancer Res* 39: 99, 2020. PMID: PMID: 32487192
63. Khatib S, Pomyen Y, Dang H, **Wang XW**. Understanding the cause and consequence of tumor heterogeneity. *Trends Cancer*, 6 (4): 267-271, 2020 (Forum); PMID: 32209440
64. Zhang K, Pomyen Y, Barry AE, Martin SP, Khatib S, Barry AE, Knight L, Forgues M, Dominguez DA, Parhar R, Shah AP, Bodzin AS, **Wang XW**, Dang H. AGO2 mediates MYC mRNA stability in hepatocellular carcinoma. *Mol Cancer Res*, 18: 612-22, 2020; PMID: 31941754
65. Dominguez DA, **Wang XW**. Impact of Next-Generation Sequencing on Outcomes in Hepatocellular Carcinoma: How Precise Are We Really? *J Hepatocellular Carcinoma*, 7: 33-7, 2020 (review); PMID: 32257970
66. Kwon SM, Budhu A, Woo HG, Chaisaingmongkol J, Dang H, Forgues M, Harris CC, Zhang G, Auslander N, Ruppin E, Mahidol C, Ruchirawat M, **Wang XW**. Functional genomic complexity defines intratumor heterogeneity and tumor aggressiveness in liver cancer. *Sci Rep* 9:16930, 2019; PMID: 31729408
67. Ma L, Hernandez MO, Zhao Y, Mehta M, Tran B, Kelly M, Rae Z, Hernandez JM, Davis JL, Martin SP, Kleiner DE, Hewitt SM, Ylaya K, Wood BJ, Greten TF, **Wang XW**. Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer. *Cancer Cell* 36: 418-30, 2019; PMID: 31588021. (cover

image featured in issue) (highly cited paper)

68. Tran TD, Cartner LK, Bokesch HR, Henrich CJ, **Wang XW**, Mahidol C, Ruchirawat S, Kittakoop P, O'Keefe BR, Gustafson KR. NMR Characterization of Rearranged Staurosporine Aglycone Analogues from the Marine Sponge *Damiria* sp. *Magn Reson Chem* 59: 534-9, 2021. PMID: 31379005
69. Fako V, Martin SP, Pomyen Y, Budhu A, Chaisaingmongkol J, Franck S, Lee JMF, Ng IQL, Cheung TT, Wei X, Liu N, Ji J, Zhao L, Liu Z, Jia HL, Tang ZY, Qin LX, Kloeckner R, Marquardt J, Greten T, **Wang XW**. Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization. *Int J Biol Sci* 15: 2654-63, 2019; PMID: 31754337
70. Yarchoan M, Agarwal P, Villanueva A, Rao S, Dawson LA, Llovet JM, Finn RS, Groopman JD, El-Serag HB, Monga SP, **Wang XW**, Karin M, Schwartz RE, Tanabe KK, Roberts LR, Gunaratne PH, Tsung A, Brown KA, Lawrence TS, Salem R, Singal AG, Kim AK, Rabiee A, Resar L, Hoshida Y, He AR, Ghoshal K, Ryan PB, Jaffee EM, Guha C, Mishra L, Coleman CN, Ahmed MM. Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. *Cancer Res* 79: 4326-30, 2019 (review); PMID: 31481419
71. Haznadar M, Diehl CM, Parker AL, Krausz KW, Bowman ED, Rabibhadana S, Forgues M, Gonzalez FJ, Mahidol C, Budhu A, **Wang XW**, Ruchirawat M, Harris CC. Urinary metabolites diagnostic of intrahepatic cholangiocarcinoma. *Cancer Epidemiol Biomarkers Prev* 28: 1704-11, 2019; PMID: 31358519
72. Kwan SY, Sheel A, Song CQ, Zhang XO, Jiang T, Dang H, Cao Y, Ozata DM, Mou H, Yin H, Weng Z, **Wang XW**, Xue W. Depletion of TRRAP induces p53-independent senescence in liver cancer by downregulating mitotic genes. *Hepatology* 71: 275-90, 2020; PMID: 31188495
73. Khatib SA and **Wang XW**. Proteomic heterogeneity reveals SOAT1 as a potential biomarker for hepatocellular carcinoma. *Transl Gastroenterol Hepatol* 4: 37, 2019 (Editorial); PMID: 31231704
74. Xue R, Chen L, Zhang C, Fujita M, Li R, Yan SM, Ong CK, Liao X, Gao Q, Sasagawa S, Li Y, Wang J, Guo H, Huang QT, Zhong Q, Tan J, Qi L, Gong W, Hong Z, Li M, Zhao J, Peng T, Lu Y, Lim KHT, Boot A, Ohno A, Chayama K, Zhang Z, Rozen SG, Teh BT, **Wang XW**, Nakagawa H, Zeng MS, Bai F, Zhang N. Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes. *Cancer Cell* 35: 932-47, 2019; PMID: 31130341
75. Chang CW, Lo JF, **Wang XW**. Roles of Mitochondria in Liver Cancer Stem Cells. *Differentiation* 107: 35-41, 2019 (Review); PMID: 31176254
76. Martin SP and **Wang XW**. The evolving landscape of precision medicine in primary liver cancer. *Hepatic Oncology* 6: HEP12, 2019 (Editorial); PMID: 31205678
77. Takai A, Dang HT, Oishi N, Khatib S, Martin SP, Dominguez DA, Luo J, Bagni R, Wu X, Powel K, Ye QH, Jia HL, Qin LX, Chen JQ, Mitchell G, Luo X, Thorgeirsson SS, **Wang XW**. Genome-wide RNAi identifies PMPCB as a therapeutic vulnerability in EpCAM⁺ hepatocellular carcinoma. *Cancer Research* 79(9): 2379-91, 2019; PMID: 30862714
78. Dang HT, Pomyen Y, Martin SP, Dominguez DA, Yim SY, Lee JS, Budhu A, Shah AA, Bozdin A, **Wang XW**. NELFE-dependent MYC signature identifies a unique cancer subtype in hepatocellular carcinoma. *Sci Rep* 9: 3369, 2019; PMID: 30833661
79. Zhu K, Tang Y, Xu X, Dang H, Tang LY, Wang X, **Wang XW**, Zhang YE. Non-proteolytic ubiquitin modification of PPAR γ by Smurf1 protects the liver from steatosis. *PLOS Biology* 16(12): e3000091, 2019;

PMID: 30566427

80. Tang W, Zhou M, Dorsey TH, Prieto D, **Wang XW**, Ruppin E, Veenstra TD, Ambs S. Integrated proteotranscriptomics of breast cancer reveals globally increased Protein-mRNA concordance associated with subtypes and survival. *Genome Med* 10(1): 94, 2018; PMID: 30501643
81. Sirica AE, Gores GJ, Groopman JD, Selaru FM, Strazzabosco M, **Wang XW**, Zhu AX. Intrahepatic cholangiocarcinoma: continuing challenges and translational advances. *Hepatology* 69: 1803-15, 2019 (review) PMID: 30251463 (highly cited paper)
82. Seehawer M, Heinzmann F, D'Artista L, Harbig J, Roux PF, Honicke L, Dang H, Klotz S, Robinson L, Dore G, Rozenblum N, Kang TW, Chawla R, Buch T, Vucur M, Roth M, Zuber J, Luedde T, Sipos B, Longerich T, Heikenwalder M, **Wang XW**, Bischof O, Zender L. Necroptosis microenvironment determines lineage commitment in liver cancer. *Nature* 562: 69-75, 2018; PMID: 30209397 (highly cited paper)
83. Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, Agdashian D, Terabe M, Berzofsky JA, Fako V, Ritz T, Longerich T, Theriot CM, McCulloch JA, Roy S, Yuan W, Thovarai V, Sen SK, Ruchirawat M, Korangy F, **Wang XW**, Trinchieri G, Greten TF. Gut Microbiome-Mediated Bile Acid Metabolism Regulates Liver Cancer via NKT Cells. *Science* 360: eaan5931, 2018; PMID: 29798856 (highly cited paper)
84. Liu J, Dang H, **Wang XW**. The significance of intertumor and intratumor heterogeneity in liver cancer. *Exp Mol Med* 50: e416, 2018. (review); PMID: 29303512
85. Petitprez F, Meunier L, Letouze E, Hoshida Y, Villanueva A, Llovet J, Thorgeirsson S, **Wang XW**, Fridman WH, Zucman-Rossi J, de Reynies A. MS.liverK: an R package for transcriptome-based computation of molecular subtypes and functional signatures in liver cancer. *bioRxiv* doi: <https://doi.org/10.1101/540005>
86. Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G, Gouw A, Kagen A, Klimstra D, Komuta M, Kondo F, Miksad R, Nakano M, Nakanuma Y, Ng I, Paradis V, Park YN, Quaglia A, Roncalli M, Roskams T, Sakamoto M, Saxena R, Sempoux C, Sirlin C, Stueck A, Thung S, Tsui WMS, **Wang XW**, Wee A, Yano H, Yeh M, Zen Y, Zucman-Rossi J, Theise N. cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. *Hepatology* 68: 113-26, 2018; PMID: 29360137 (highly cited paper)
87. Zheng H, Pomyen Y, Hernandez MO, Li C, Livak F, Tang W, Dang H, Greten TF, Davis JL, Zhao Y, Mehta M, Levin Y, Shetty J, Tran B, Budhu A, **Wang XW**. Single cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. *Hepatology* 68: 127-40, 2018; PMID: 29315726 (highly cited paper)
88. Nepal C, O'Rourke CJ, Oliveira D VNP, Shema S, Taranta A, Calderaro J, Barbour A, Raggi C, **Wang XW**, Lautem A, Roberts LR, Andersen JB. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. *Hepatology* 68: 949-63, 2018; PMID: 29278425
89. Xue R, Li J, Bai F, **Wang XW**, Ji J, Lu YY. A race to uncover a panoramic view of primary liver cancer. *Cancer Biology & Medicine* 14: 335-40, 2017. (commentary). PMID: 29372099
90. Fako V, **Wang XW**. The status of TACE treatment in the era of precision oncology. *Hepatic Oncology* 4: 55-63, 2017. (review) PMID: 28989699
91. Sun Y, Ji F, Kumar MR, Zheng X, Xiao Y, Liu N, Shi J, Wong L, Forgues M, Qin LX, Tang ZY, Zhao X, **Wang XW**, Ji J. Transcriptome integration analysis in hepatocellular carcinoma reveals discordant intronic miRNA-host gene pairs in expression. *International Journal of Biological Sciences* 13: 1438-49, 2017;

PMID: 29209147

92. Dang H, Takai A, Forgues M, Pomyen Y, Mou H, Xue W, Ray D, Ha KCH, Morris QD, Hughes TR, **Wang XW**. Oncogenic activation of RNA binding protein NELFE and MYC signaling in hepatocellular carcinoma. *Cancer Cell* 32: 101-14.e8, 2017; PMID: 28697339
93. Liu J, Kruswick A, Dang H, Tran AD, Kwon SM, **Wang XW**, Oberdoerffer P. Ubiquitin-specific protease 21 stabilizes BRCA2 to control DNA repair and tumor growth. *Nature Communications* 8: 137, 2017; PMID: 28743957
94. Chaisaingmongkol J, Budhu A, Dang H, Rabibhadana S, Pupacdi B, Kwon SM, Forgues M, Bhudhisawasdi V, Lertprasertsuke N, Chotirosniramit A, Pairojkul C, Auewarakul CU, Sricharunrat T, Phornphutkul K, Sangrajrang S, Cam M, He P, Hewitt SM, Ylaya K, Wu X, Andersen JB, Thorgeirsson SS, Waterfall JJ, Zhu YJ, Walling J, Stevenson HS, Meltzer PS, Loffredo CA, Hama N, Shibata T, Wiltrout RH, Harris CC, Mahidol C, Ruchirawat M, **Wang XW**. Common molecular subtypes among Asian hepatocellular and cholangiocarcinoma. *Cancer Cell* 32: 57-70.e3, 2017; PMID: 28648284
95. Song C, Li Y, Mou H, Moore J, Moore J, Park A, Pomyen Y, Hough S, Kennedy Z, Fischer A, Yin H, Anderson DG, Conte D, Zender L, **Wang XW**, Thorgeirsson SS, Weng Z, Xue W. Genome-wide CRISPR screen identifies regulators of MAPK as suppressors of liver tumors in mice. *Gastroenterology* 152: 1161-73, 2017; PMID: 27956228
96. Eggert T, Wolter K, Ji J, Ma C, Yevsa T, Klotz S, Medina-Echeverz J, Longerich T, Forgues M, Reisinger F, Heikenwalder M, **Wang XW**, Zender L, Greten TF. Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor progression. *Cancer Cell* 30: 533-47, 2016; PMID: 27728804
97. Auslander N, Yizhak K, Weinstock A, Budhu A, Tang W, **Wang XW**, Ambs S, Ruppin E. A joint analysis of transcriptomic and metabolomic data uncovers enhanced enzyme-metabolite coupling in breast cancer. *Scientific Reports* 6: 29662, 2016; PMID: 27406679
98. Ploeger C, Waldburger N, Fraas A, Goepfert B, Pusch S, Breuhahn K, **Wang XW**, Schirmacher P, Roessler S. Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukin-6 signaling in hepatocellular carcinoma. *Hepatology* 64: 828-42, 2016; PMID: 27311882
99. Ye QH, Zhu WW, Zhang JB, Qin Y, Lu M, Lin GL, Guo L, Zhang B, Lin ZH, Roessler S, Forgues M, Jia HL, Lu L, Zhang XF, Lian BF, Xie L, Dong QZ, Tang ZY, **Wang XW**, Qin LX. GOM1 modulates EGFR/RTK cell-surface recycling to drive hepatocellular carcinoma metastasis. *Cancer Cell* 30: 444-58, 2016; PMID: 27569582
100. Wang R, Zhao T, Cui K, Hu G, Chen Q, Chen W, **Wang XW**, Soto-Gutierrez A, Zhao K, Deng C. Negative reciprocal regulation between Sirt1 and Per2 modulates the circadian clock and aging. *Scientific Reports* 6: 28633, 2016; PMID: 27346580
101. Fako V, Yu Z, Henrich CJ, Ransom T, Budhu AS, **Wang XW**. Inhibition of wnt/ β -catenin signaling in hepatocellular carcinoma by an antipsychotic drug pimozide. *International Journal of Biological Sciences* 12: 768-75, 2016; PMID: 27313491
102. Takai A, Fako V, Dang H, Forgues M, Yu Z, Budhu A, **Wang XW**. Three-dimensional organotypic culture models of human hepatocellular carcinoma. *Scientific Reports* 6: 21174, 2016. PMID: 26880118
103. Scarzello AJ, Jiang Q, Back T, Hodge D, Dang H, Subleski J, Roan S, Weiss JM, Stauffer J, Chaisaingmongkol J, Rabibhadana S, Ruchirawat M, Ortaldo J, **Wang XW**, Norris PS, Ware CF, Wiltrout RH. LT β R signaling

preferentially accelerates oncogenic AKT-initiated liver tumors. *Gut* 65: 1765-75, 2016. PMID: 26206664

104. Zhao X, Ji J, Yu LR, Veenstra TV, **Wang XW**. Cell cycle-dependent phosphorylation of nucleophosmin and its potential regulation by peptidyl-prolyl cis/trans isomerase. *Journal of Molecular Biochemistry* 4: 95-103, 2015. PMID: 27099843
105. Lee YK, Jee BA, Kwon SM, Yoon YS, Xu WG, Wang HJ, **Wang XW**, Thorgeirsson SS, Lee JS, Woo HG, Yoon G. Identification of a mitochondrial defect gene signature reveals NUPR1 as a key regulator of liver cancer progression. *Hepatology* 62: 1174-89, 2015. PMID: 26173068
106. Xue W and **Wang XW**. The search for precision models clinically relevant to human liver cancer. *Hepatic Oncology* 2: 315-9, 2015. (review) PMID: 30191010
107. Zhao X, Parpart S, **Wang XW**. The importance of integrated genomics to uncover clinically-relevant cancer driver genes. *Molecular & Cellular Oncology* 3: e1019975, 2015. (commentary) PMID: 27308534
108. Greten TF, **Wang XW**, Korangy F. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. *Gut* 64: 842-8, 2015. (review) PMID: 25666193
109. Bian CB and **Wang XW**. Targeting heterogeneity in hepatocellular carcinoma. *Oncology News* 10 (1): 15-6, 2015. (review)
110. Ji J, Zheng X, Forgues M, Yamashita T, Wauthier E, Reid LM, Wen X, Song Y, Wei J, Khan J, Thorgeirsson SS, **Wang XW**. Identification of MicroRNAs Specific for EpCAM+ Tumor Cells in Hepatocellular Carcinoma. *Hepatology* 62: 829-40, 2015. PMID: 25953724
111. Ji JL, Eggert T, Budhu A, Forgues M, Takai A, Ye QH, Lee JS, Kim JH, Greten TF, **Wang XW**. Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma. *Hepatology* 62: 481-95, 2015. PMID: 25833323
112. Lu YY, Xu W, Ji J, Feng D, Sourbier C, Yang Y, Li C, Qu J, Zeng, Z, Wang C, Chang X, Chen Y, Mishra A, Xu M, Lee MJ, Lee S, Trepel J, Linehan WM, **Wang XW**, Yang Y, Neckers L. Alternative splicing of the cell-fate determinant Numb in hepatocellular carcinoma. *Hepatology* 62: 1122-31, 2015
113. Tao J, Ji J, Li L, Wu H, **Wang XW**, Calvisi DF, Song G and Chen X. Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer. *Oncotarget* 6: 6977-88, 2015. PMID: 25762642
114. Zhao X, Parpart S, Takai A, Roessler S, Budhu A, Yu Z, Blank M, Zhang YE, Jia HL, Ye QH, Qin LX, Tang ZY, Thorgeirsson SS and **Wang XW**. Integrative Genomics Identifies YY1AP1 as an Oncogenic Driver in EpCAM⁺ AFP⁺ Hepatocellular Carcinoma. *Oncogene* 34: 5095-104, 2015. PMID: 25597408
115. Roessler S, Lin G, Forgues M, Budhu A, Hoover S, Simpson RM, Wu X, He P, Qin LX, Tang ZY, Ye QH, **Wang XW**. Integrative Genomic and Transcriptomic Characterization of Matched Primary and Metastatic Liver and Colorectal Carcinoma. *International Journal of Biological Sciences* 11: 88-98, 2015. PMID: 25552933. (cover image featured in issue)
116. Li L, Liu Y, Guo Y, Liu B, Zhao Y, Li P, Song F, Zheng H, Yu J, Song T, Niu R, Li Q, Winkler H, **Wang XW**, Zhang W, Chen K. Regulatory miR-148a-ACVR1/BMP circuit defines a cancer stem cell-like aggressive subtype of hepatocellular carcinoma. *Hepatology* 61: 574-84, 2015. PMID: 25271001
117. Itzel T, Scholz P, Maass T, Krupp M, Marquardt JU, Strand S, Becker D, Staib F, Binder H, **Wang XW**, Thorgeirsson SS, Galle PR, Teufel A. Translating bioinformatics in oncology: Guilty by profiling meta-

- analysis and identification of KIF18B and CDCA3 as novel driver genes in carcinogenesis. *Bioinformatics* 31: 216-24, 2015. PMID: 25236463
118. Takai A, Dang HT, **Wang XW**. Identificatin of drivers from cancer genome diversity in hepatocellular carcinoma. *Int J Mol Sci* 15:11142-60, 2014. (review) PMID: 24955791
 119. **Wang XW** and Thorgeirsson SS. The biological and clinical challenge of liver cancer heterogeneity. *Hepatic Oncology* 1: 349-53, 2014. (review) PMID: 30190968
 120. Roessler S, Budhu A and Wang XW. Deciphering cancer heterogeneity: the biological space. *Frontiers in Cell and Developmental Biology* 2 (12): 1-5, 2014. (review) PMID: 25364720
 121. Dang H, Budhu A and **Wang XW**. The origin of cancer stem cells. *Journal of Hepatology* 60: 1304-5, 2014. (commentary) PMID: 24631602
 122. Kim JH, Sohn BH, Lee HS, Kim SB, Yoo JE, Park YY, Jeong W, Lee SS, Park ES, Kaseb A, Kim BH, Kim WB, Yeon JE, Byun KS, Chu IS, Kim SS, **Wang XW**, Thorgeirsson SS, Luk JM, Kang KJ, Heo J, Park YN, Lee JS. Genomic Predictors for Two Distinct Recurrence Patterns of Hepatocellular Carcinoma: Model Derivation and Validation. *PLOS Medicine* 11: e1001770, 2014. PMID: 25536056
 123. Budhu A, Terunuma A, Zhang G, Hussain P, Ambs S, **Wang XW**. Metabolic profiles are principally different between cancers of the liver, pancreas and breast. *International Journal of Biological Sciences* 10: 966-72, 2014. PMID: 25210494
 124. Giang HN, Tang W, Robles AI, Beyer R, Gray LT, Welsh JA, Schetter AJ, Kumamoto K, **Wang XW**, Hickson ID, Malzels N, Monnat RJ, Harris CC. Regulation of gene expression by the BLM helicase correlates with the presence of G-quadruplex DNA motifs. *Proc Nat'l Acad Sci USA* 111: 9905-10, 2014. PMID: 24958861
 125. Parpart S, Roessler S, Dong F, Rao V, Takai A, Ji J, Qin LX, Ye QH, Jia HL, Tang ZY, **Wang XW**. Modulation of miR-29 Expression by Alpha-fetoprotein is linked to the Hepatocellular Carcinoma Epigenome. *Hepatology* 60: 872-83, 2014. PMID: 24798303
 126. Yamashita T, Kitao A, Matsui O, Hayashi T, Nio K, Yamashita T, Mizukoshi E, Honda M, Nakanuma Y, Takamura H, Ohta T, Yamamoto M, Takayama T, Arai S, **Wang XW**, Kaneko S. Gd-EOB-DTPA-enhanced Magnetic Resonance Imaging and Alpha-fetoprotein Predict Prognosis of Early-Stage Hepatocellular Carcinoma. *Hepatology* 60: 1674-85 2014. PMID: 24700365
 127. Yamashita T and **Wang XW**. Cancer stem cells in the development of liver cancer, *Journal of Clinical Investigation* 123:1911–8, 2013. (review). PMID: 23635789 (highly cited paper)
 128. Parpart S and **Wang XW**. microRNA regulation and its consequences in cancer. *Current Pathology Reports* 1: 71-9, 2013. (review). PMID: 23420713
 129. Hsiao TH, Chen HHH, Roessler S, **Wang XW**, Chen Y. Identification of genomic functional hotspots with copy number alteration in liver cancer. *EURASIP Journal on Bioinformatics and Systems Biology* 1: 14, 2013. PMID: 24160471
 130. Ozdemir B, Abd-Almageed W, Roessler S, **Wang XW**. iSubgraph: Integrative genomics for subgroup discovery in hepatocellular carcinoma using graph mining and mixture models. *PLoS ONE* 8: e78624, 2013. PMID: 24223834
 131. Zhu WW, Guo J, Guo L, Jia H, Zhu M, Zhang JB, Loffredo C, Forgues M, Huang H, Xing X, Ren N, Dong

- QZ, Zhou H, Ren Z, Zhao N, **Wang XW**, Tang ZY, Qin LX, Ye QH. Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma. *Clinical Cancer Research* 19: 3944-54, 2013. PMID: 23719264
132. Henrich CJ, Budhu A, Yu Z, Evans JR, Goncharova EI, Ransom TR, **Wang XW**, McMahon JB. High-throughput screening for identification of inhibitors of EpCAM-dependent growth of hepatocellular carcinoma cells. *Chemical Biology & Drug Design* 82: 131-9, 2013. PMID: 23879724
133. Ji, J, Yu L, Yu, Z, Forgues M, Uenishi K, Kubo S, Zhou J, Fan J, Tang ZY, Fu S, Zhu H, Jin JG4, Sun HC, **Wang XW**. Development of a miR-26 Companion Diagnostic Test for Adjuvant Interferon-alpha Therapy in Hepatocellular Carcinoma. *International Journal of Biological Sciences* 9: 303-12, 2013. PMID: 23569435
134. Feng M, Gao W, Wang R, Chen W, Man YG, Fig WD, **Wang XW**, Dimitrov DS, Ho M. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. *Proc Nat'l Acad Sci USA* E1083-91, 2013. PMID: 23471984
135. Budhu A, Roessler S, Zhao X, Yu Z, Forgues M, Ji J, Karoly E, Qin LX, Ye QH, Jia HL, Fan J, Sun HC, Tang ZY, **Wang XW**. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. *Gastroenterology* 144: 1066-75, 2013. PMID: 23376425
136. Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K, Hara Y, Zeng SS, Hayashi T, Kondo M, Takatori H, Yamashita T, Mizukoshi E, Ikeda H, Zen Y, Takamura H, **Wang XW**, Kaneko S. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. *Hepatology* 57: 1484-97, 2013. PMID: 23174907
137. Oikawa T, Kamiya A, Zeniya M, Chikada H, Hyuck AD, Yamazaki Y, Wauthier E, Tajiri H, Miller LD, **Wang XW**, Reid LM, Nakauchi H. SALL4 as an indicator of cancer stem cells in liver cancer. *Hepatology* 57: 1469-83, 2013. PMID: 23175232
138. Zhao Y, Schetter AJ, Yang GB, Nguyen G, Mathe EA, Li P, Cai H, Yu L, Liu F, Hang D, Yang H, **Wang XW**, Ke Y, Harris CC. Inflammatory and microRNA gene expression as prognostic marker for overall survival in esophageal squamous cell carcinoma. *International Journal of Cancer* 132: 2901-09, 2013. PMID: 23175214
139. Budhu A and **Wang XW**. Transforming the microenvironment: a trick of the metastatic cancer cell. *Cancer Cell* 22: 279-80, 2012. (commentary). PMID: 22975368
140. Ji J and **Wang XW**. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. *Seminars in Oncology* 39: 461-72, 2012. (review). PMID: 22846863
141. **Wang XW**, Heegaard NHH, Orum H. microRNAs in liver disease. *Gastroenterology* 142: 1431-43, 2012 (review). PMID: 22504185
142. Budhu A, **Wang XW**. At the cancer steering wheel: defining key genomic drivers of liver cancer with next generation sequencing. *Journal of Hepatology* 56: 1412-4, 2012 (commentary). PMID: 22286003
143. Oishi N, Kumar MR, Roessler S, Ji J, Forgues M, Budhu A, Zhao X, Andersen JB, Ye QH, Jia HL, Qin LX, Yamashita T, Woo HG, Kim YJ, Kaneko S, Tang ZY, Thorgeirsson SS, **Wang XW**. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of mir-200c and EMT in intrahepatic cholangiocarcinoma. *Hepatology* 56: 1792-1803, 2012. PMID: 22707408

144. Xue W, Kitzing TM, Roessler S, Zuber J, Krasnitz A, Schultz N, Revill K, Weismueller S, Rappaport A, Simon J, Zhang J, Luo W, Hicks J, Zender L, **Wang XW**, Powers S, Wigler M, Lowe SW. A cluster of cooperating tumor suppressor gene candidates in chromosomal deletions. *Proc Nat'l Acad Sci USA* 109: 8212-7, 2012. PMID: 22566646
145. Zhao F, Hoechst B, Gamrekelashvili J, Ormandy L, Voigtlander T, Wedemeyer H, Ylaya K, **Wang XW**, Hewitt SM, Manns MP, Korangy F, Greten TF. Human CCR4+CCR6+ TH17 cells suppress autologous CD8+ T cell responses. *Journal of Immunology* 188: 6055-62, 2012. PMID: 22615204
146. Kim SM, Leem SH, Chu IS, Park YY, Kim SC, Kim SB, Park ES, Lim JY, Heo J, Kim YJ, Kim DG, Kaseb A, Park YN, **Wang XW**, Thorgeirsson SS, Lee JS. Sixty-Five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. *Hepatology* 55: 1443-52, 2012. PMID: 22105560
147. Roessler S, Long EL, Budhu A, Chen Y, Zhao X, Ji J, Walker R, Jia HJ, Ye QH, Qin LX, Tang ZY, He P, Hunter KW, Thorgeirsson SS, Meltzer PS, **Wang XW**. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. *Gastroenterology* 142: 957-66, 2012. PMID: 22202459
148. Oishi N and **Wang XW**. Novel therapeutic strategies for targeting liver cancer stem cells. *International Journal of Biological Sciences* 7: 517-35, 2011 (review). PMID: 21552419
149. Kumar M, Zhao X, **Wang XW**. Molecular carcinogenesis of hepatocellular carcinoma and cholangiocarcinoma. *Cell & Bioscience* 1: 5, 2011 (*Highly Accessed*) (review). PMID: 21711594
150. Budhu A and **Wang XW**. MicroRNAs and gastroenterological cancers. *Drug Discovery Today Dis Mech* 8: e95-e102, 2011 (review). PMID: 22582080
151. Budhu A and **Wang XW**. Power Play: Scoring our goals for liver cancer with better GWAS study design. *Journal of Hepatology* 54: 823-4, 2011. (commentary). PMID: 21167853
152. Budhu A, Ji J, **Wang XW**. The clinical potential of microRNAs. *Journal of Hematology & Oncology* 3: 37, 2010 (*Highly accessed*) (review). PMID: 20925959
153. Kim HS, Vassilopoulos A, Wang RH, Lahusen JT, Xiao Z, Xu X, Li C, Veenstra TD, Ji J, **Wang XW**, Park SH, Cha YI, Gius D, Deng CX. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. *Cancer Cell* 20: 487-99, 2011. PMID: 22014574
154. Ji J, Yamashita T, **Wang XW**. Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. *Cell & Bioscience* 1: 4, 2011 (*Highly Accessed*). PMID: 21711587
155. Woo HG, **Wang XW**, Budhu A, Kim YH, Kwon SM, Tang ZY, Sun ZT, Harris CC, Thorgeirsson SS. Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. *Gastroenterology* 140: 1063-70, 2011. PMID: 21094160
156. Ji J, **Wang XW**. A Yin-Yang Balancing Act of the Lin28/Let-7 Link in Tumorigenesis. *Journal of Hepatology* 53: 974-5, 2010 (review). PMID: 20739081
157. **Wang XW**, Ji J, Budhu A, Sun HC. Reply to: MicroRNA analysis for outcome prediction in hepatitis B virus-related liver cancer by Boix L & Bruix J. *Gastroenterology* 138: 1626-7, 2010.
158. Cairo S, Wang Y, Reynies AD, Duroure K, Dahan J, Redon MJ, Fabre M, McClelland M, **Wang XW**, Croce C, Buendia MA. A stem cell-like microRNA signature driven by Myc in aggressive liver cancer. *Proc Nat'l*

Acad Sci USA 107: 20471-6, 2010. PMID: 21059911.

159. Yu L, Feng M, Kim H, Phung H, Kleiner DE, Gores GJ, Qian M, **Wang XW**, Ho M. Mesothelin as a potential therapeutic target in Human Cholangiocarcinoma. *Journal of Cancer* 1: 141-9, 2010. PMID: 20922056
160. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Tang ZY, Qin LX, **Wang XW**. A Unique Metastasis Gene Signature Enables Prediction of Tumor Relapse in Early-Stage Hepatocellular Carcinoma Patients. *Cancer Research* 70: 10202-12, 2010. PMID: 21159642
161. Nguyen GH, Schetter AJ, Chou DB, Bowman ED, Zhao R, Hawkes JE, Mathe EA, Kumanoto K, Zhao Y, Budhu A, Hagiwara N, **Wang XW**, Miyashita M, Casson AG, Harris CC. Inflammatory and microRNA Gene Expression as Prognostic Classifiers of Barrett's Associated Esophageal Adenocarcinoma. *Clinical Cancer Research* 16: 5824-34, 2010. PMID: 20947516
162. Ji J, Zhao L, Budhu A, Forgues M, Jia HL, Qin LX, Ye QH, Yu J, Shi X, Tang ZY, **Wang XW**. Let-7g targets collagen type I $\alpha 2$ and inhibits cell migration in hepatocellular carcinoma. *Journal of Hepatology* 52: 690-7, 2010. PMID: 20338660
163. Jiang W, **Wang XW**, Unger T, Forgues M, Kim JW, Hussain SP, Bowman E, Spillare EA, Lipsky MM, Meck JM, Cavalli LR, Haddad BR, Harris CC. Cooperation of tumor-derived HBx mutants and p53-249^{ser} mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line. *International Journal of Cancer* 127: 1011-20, 2010. PMID: 20017137
164. **Wang XW** and Thorgeirsson SS. Genome-based predictors for HCC outcomes: A matter of tumor and/or stroma. *Journal of Hepatology* 51: 596-7, 2009. (commentary). PMID: 20625453
165. **Wang XW** and Thorgeirsson SS. Transcriptome analysis of liver cancer: Ready for the clinic? *Journal of Hepatology* 50: 1060-4, 2009. (commentary). PMID: 19328580
166. Ji J and **Wang XW**. What Is the Relationship among MicroRNA-181, Epithelial Cell-Adhesion Molecule (EpCAM) and b-Catenin in Hepatic Cancer Stem Cells (Authors' reply). *Hepatology* 50: 2048, 2009.
167. Ji J and **Wang XW**. New kids on the block: diagnostic and prognostic microRNAs in hepatocellular carcinoma. *Cancer Biology & Therapy* 8: 1686-93, 2009. (review). PMID: 19901517
168. Dong F, Budhu A, **Wang XW**. Translating the Metastasis Paradigm from Scientific Theory to Clinical Oncology. *Clinical Cancer Research* 15: 2588-93, 2009. (review). PMID: 19351761
169. Mathe EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D, Altorki NK, Casson AG, Liu CG, **Wang XW**, Yanaihara N, Hagiwara N, Dannenberg AJ, Miyashita M, Croce CM, Harris CC. MiRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus and associations with survival. *Clinical Cancer Research* 15: 6192-200, 2009. PMID: 19789312
170. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IOL, Fan J, Tang ZY, Sun HC, **Wang XW**. MicroRNA expression, survival, and response to interferon in men and women with liver cancer. *New England Journal of Medicine* 361: 1437-47, 2009. (Listed as the top 10 health stories of 2009 by the Harvard Health Publications). PMID: 19812400
171. Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, Deng CX, Wauthier E, Reid LM, Ye QH, Qin LX, Yang W, Wang HY, Tang, ZY, Croce CM and **Wang XW**. Identification of MicroRNA-181 by Genome-

Wide Screening as a Critical Player in Epithelial Cell Adhesion Molecule–Positive Hepatic Cancer Stem Cells. *Hepatology* 50: 472-80, 2009. PMID: 19585654

172. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang H, Jia H, Ye Q, Qin L, Wauthier E, Reid L, Minato H, Honda M, Kaneko S, Tang Z, **Wang XW**. EpCAM-positive hepatocellular carcinoma cells are tumor initiating cells with stem/progenitor cell features. *Gastroenterology* 136: 1012-24, 2009 (*The 2nd most downloaded articles from the journal on Science Direct for the period of Jan-Mar 2009*). PMID: 19150350
173. Wang RH, Sengupta K, Li C, Kim HS, Cao L, Xiao C, Kim S, Xu X, Zheng Y, Chilton B, Zheng ZM, **Wang XW**, Ried T, Deng CX. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. *Cancer Cell* 14: 312-23, 2008. PMID: 18835033
174. Yamashita T, Forgues M, Kim JW, Wang W, Ye QH, Jia HL, Budhu A, Takafuji VA, Zanetti K, Chen Y, Qin LX, Tang ZY, **Wang XW**. EpCAM and a-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. *Cancer Research* 68: 1451-61, 2008. PMID: 18316609
175. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, Zanetti KA, Ye QH, Qin LX, Croce CM, Tang ZY, **Wang XW**. Identification of metastasis-related microRNAs in hepatocellular carcinoma. *Hepatology* 47: 897-907, 2008. PMID: 18176954
176. Roessler S, Budhu A, **Wang XW**. The future of molecular profiling of human hepatocellular carcinoma. *Future Oncology* 3: 429-439, 2007. (review). PMID: 17661718
177. Hussain SP, Schwank J, Staib F, **Wang XW**, Harris CC. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. *Oncogene* 26: 2166-76, 2007. (review). PMID: 17401425
178. Yamashita T, Forgues Budhu A, **Wang XW**. Activation of hepatic stem cell marker EpCAM by Wnt-b-catenin signaling in hepatocellular carcinoma. *Cancer Research* 67: 10831-9, 2007. PMID: 18006828
179. Yoshikawa H, Matsubara K, Zhou X, Okamura S, Kubo T, Murase Y, Shikauchi Y, Esteller M, Herman JG, **Wang XW**, Harris CC. WNT10B functional dualism: b-catenin/Tcf-dependent growth promotion or independent suppression with deregulated expression in cancer. *Molecular Biology of Cell* 18: 4292-303, 2007. PMID: 17761539
180. Seike M, Yanaihara N, Bowman ED, Zanetti KA, Mechanic LE, Budhu A, Kumamoto K, Yokota J, Gemma A, Kudoh S, **Wang XW**, Harris CC. A cytokine gene signature of the lung environment predicts lymph node metastasis and prognosis of lung adenocarcinoma. *Journal of National Cancer Institute* 99: 1257-69, 2007. PMID: 17686824
181. Budhu A, Chen Y, Kim JW, Forgues M, Valerie K, Harris CC and **Wang XW**. Gene expression profiling of primary human hepatocytes expressing hepatitis C viral proteins. *Carcinogenesis* 28: 1552-60, 2007. PMID: 17404395
182. Chen XC, Yu B, Dong JC, Gu YX, Chen L, Wu QZ, Hou NP, Liu JX, Xu JT, Jin RX, Jin GQ, Yang XD, Cao YW, Tan JJ, Zhu B, Shen JC, Xu Z, Varticovski L and **Wang XW**. A Phase II Clinical Trial with Cytotropic Heterogeneous Molecular Lipids (CHML) for Patients with Hepatic Malignancies. *Anticancer Research* 27: 1593-1600, 2007. PMID: 17595781
183. Takafuji V, Forgues M, Unsworth E, Goldsmith P, **Wang XW**. A 5-kD osteopontin segment cleaved by matrix metalloproteinase-9 activity is essential for tumor cell invasion in hepatocellular carcinoma. *Oncogene* 26:

6361-71, 2007. PMID: 17452979

184. Jia, H.L., Ye, Q.H., Qin, L.X., Budhu, A., Forgues, M., Chen, Y., Liu, X.K., Sun, H.C., Wang, L., Tang, Z.Y. and **Wang, X.W.** Gene Expression Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma Including Those with Normal Serum Alpha-Fetoprotein and Small Tumors. *Clinical Cancer Research* 13: 1133-9, 2007. PMID: 17317821
185. Lim MJ and **Wang XW.** Nucleophosmin and human cancer. *Cancer Detection and Prevention* 30: 481-90, 2006. (review). PMID: 17113241
186. Budhu A and **Wang XW.** Role of cytokines in hepatocellular carcinoma. *Journal of Leukocyte Biology* 80: 1197-213, 2006. (review). PMID: 16946019
187. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY, and **Wang XW.** Prediction of metastatic potential and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. *Cancer Cell* 10, 99-111, 2006. PMID: 16904609
188. Lambaa JK, Chen X, Lan LB, Kim JW, **Wang XW**, Relling MV Kazuto Y, Watkins PB, Strom S, Sun D, Schuetz JD and Schuetz EG. Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans. *Pharmacogenetics and Genomics* 16: 415-427, 2006. PMID: 16708050
189. Wu CG, Budhu A, Chen S, Zhou X, Ionescu NC, Valerie K and **Wang XW.** Effect of Hepatitis C virus Core Protein on the Molecular Profiling of Human B lymphocyte. *Molecular Medicine* 12: 47-53, 2006. PMID: 16838065
190. Staib F, Robles AI, Varticovski L, **Wang XW**, Sirotin N, Zhurkin VB, Hofseth LJ, Hussain SP, Galle PR, and Harris CC. The p53 tumor suppressor network is a key responder to microenvironment components of chronic inflammation stress. *Cancer Research* 65: 10255-10264, 2005. PMID: 16288013
191. Spillare EA, **Wang XW** von Kobe C, Bohr VA, Hickson ID and Harris CC. Redundancy of DNA helicases in p53-mediated apoptosis. *Oncogene* 25, 2119-23, 2006. PMID: 16288211
192. Budhu AS and **Wang XW.** Loading and Unloading: Orchestrating Centrosome Duplication and Spindle Assembly by Ran/Crm1. *Cell Cycle* 4: 1508-12 2005. (review). PMID: 16294017
193. Budhu AS, Zipser B, Forgues M, Ye QH, Sun Z, **Wang XW.** The Molecular signature of metastases of human hepatocellular carcinoma. *Oncology* 69 (S2), 2005. (review). PMID: 16210873
194. Wang W, Budhu A, Forgues M, and **Wang XW.** Temporal and spatial control of nucleophosmin by the Ran/Crm1 complex in centrosome duplication. *Nature Cell Biology* 7: 823-30, 2005. PMID: 16041368
195. Zhang Y, **Wang XW**, Yu MH, Nakanishi T, Kainate D, Jelovic D, Goulbeva O, Ross DD, Brodie A and Hamburger AW. The ErbB3 binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. *Proc Nat'l Acad Sci USA* 102: 9890-5, 2005. PMID: 15994225
196. Staib F, Robles AL, Varticovski L, **Wang XW**, Hussain P, Harris CC. P53-dependent gene expression profiles in response to different types of cellular stress. *Free Radical Biology & Medicine* 37: S72-S73, 2004. (review).
197. Hofseth LJ, Robles AI, Yang Q, **Wang XW**, Hussain SP, Harris CC. p53: at the crossroads of molecular carcinogenesis and molecular epidemiology. *Chest* 125: 83S-5S, 2004. PMID: 15136428
198. Budhu AS, Zipser B, Forgues M, Ye QH, Qin LX, Tang ZY, Chen Y, Simon R, Sun Z, **Wang XW.** The

- Molecular signature of metastases of human hepatocellular carcinoma. *Toxicologic Pathology* 32: 730-731, 2004. (review).
199. Ye QH, Tang ZY, Qin LX, Ma ZC, Wu ZQ, Ye SL, Liu YQ, Fan J, **Wang XW**. Application of genechip technology in identification of metastasis-associated genes for hepatocellular carcinoma. *Chinese Journal of Hepatobiliary Surgery* 10: 679-82, 2004. (review)
 200. Kim JW, Ye QH, Forgues M, Chen Y, Budhu A, Sime J, Hofseth LJ, Kaul R and **Wang XW**. Cancer-associated molecular signatures in the cirrhotic tissue samples of patients with chronic liver disease. *Hepatology* 39: 518-27, 2004. PMID: 14768006
 201. Yang Q, Zhang R, **Wang XW**, Linke SP, Sengupta S, Hickson ID, Pedrazzi G, Perrera C, Stagljar I, Littman SJ, Modrich P, and Harris CC. The mismatch DNA repair heterodimer, hMSH2/6, regulates BLM helicase in homologous DNA recombination. *Oncogene* 23: 3749-3756, 2004. PMID: 15064730
 202. Kim JW and **Wang XW**. Gene expression profiling of preneoplastic liver disease and liver cancer: a new era for improved early detection and treatment of these deadly diseases? *Carcinogenesis* 24: 363-369, 2003. (review). PMID: 12663493
 203. Staib F, Hussain SP, Hofseth LJ, **Wang XW** and Harris CC. p53 and liver carcinogenesis. *Human Mutation* 21, 201-216, 2003. (review). PMID: 12619106
 204. **Wang XW**, Hussain SP, Huo TI, Wu CG, Forgues M, Hofseth LJ, Brechot C, Harris CC. Molecular pathogenesis of human hepatocellular carcinoma. *Toxicology* 181-182: 43-47, 2002 (*The top ten of most downloaded articles within the toxicology category of all articles published in Elsevier journals in 2003*). (review). PMID: 12505283
 205. Ashktorab H, Ahmed A, Littleton G, **Wang XW**, Allen CR, Tackey R, Walters C, Smoot DT. p53 and p14 increase sensitivity of gastric cells to H. pylori-induced apoptosis. *Digestive Diseases and Sciences* 48: 1284-91, 2003. PMID: 12870784
 206. Forgues M, Difilippantonio MJ, Linke SP, Ried T, Nagashima K, Feden J, Valerie K, Fukasawa K, **Wang XW**. Involvement of Crm1 in HBx-induced aberrant centriole replication and abnormal mitotic spindles. *Molecular and Cellular Biology* 23: 5282-5292, 2003. PMID: 12861014
 207. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY and **Wang XW**. Predicting Hepatitis B Virus-Positive Metastatic Hepatocellular Carcinomas Using Gene Expression Profiling and Supervised Machine Learning. *Nature Medicine* 9: 416-423, 2003. PMID: 12640447. (Featured in cover)
 208. Linke SP, Sengupta S, Khabie N, Jeffries BA, Buchhop S, Miska S, Henning W, Pedoux R, **Wang XW**, Hofseth LJ, Yang Q, Garfield SH, Sturzbecher HW, and Harris CC. p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination. *Cancer Research* 63: 2596-2605, 2003. PMID: 12750285
 209. Wu CG, Forgues M, Siddique S, Farnsworth J, Kristoffer V, **Wang XW**. SAGE transcript profiles of normal primary human hepatocytes expressing oncogenic hepatitis B virus X protein. *FASEB Journal* 16: 1665-7, 2002. PMID: 12207007
 210. Yang Q, Zhang R, **Wang XW**, Spillare EA, Linke SP, Subramanian D, Griffith JD, Li JL, Hickson ID, Shen JC, Loeb LA, Mazur SJ, Appella E, Brosh RM, Karmakar P, Bohr VA, Harris CC. The processing of holliday junctions by BLM and WRN helicases is regulated by p53. *Journal of Biological Chemistry* 277: 31980-

31987, 2002. PMID: 12080066

211. **Wang XW**. Microinjection technique used to study functional interaction between p53 and hepatitis B virus X gene in apoptosis. *Molecular Biotechnology* 18: 169-177, 2001. (review). PMID: 11471458
212. Forgues M, Marogi A, Wu C, Spillare E, Yang Q, Yoshida M, **Wang XW**. Interaction of the hepatitis B virus X protein with the Crm1-dependent nuclear export pathway. *Journal of Biological Chemistry* 276: 22797-22803, 2001. PMID: 11287420
213. Wu CG, Salvay DM, Forgues M, Valerie K, Farnsworth J, Markin RS and **Wang XW**. Distinctive gene expression profiles associated with hepatitis B virus X protein. *Oncogene* 20: 3674-3682, 2001.
214. Nagashima M, Shiseki M, Miura K, Hagiwara K, Linke SP, Pedoux R, **Wang XW**, Yokota J, Riabowol K and Harris CC. DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. *Proc Nat'l Acad Sci USA* 98: 9671-9676, 2001. PMID: 11481424
215. **Wang XW**, Tseng A, Ellis NA, Spillare EA, Linke SP, Robles AI, Seker H, Yang Q, Hu P, Beresten S, Bemmels NA, Garfield S and Harris CC. Functional interaction of p53 and BLM DNA helicase in apoptosis. *Journal of Biological Chemistry* 276: 32948-32955, 2001. PMID: 11399766
216. Brosh RM Jr, Karmakar P, Sommers JA, Yang Q, **Wang XW**, Spillare EA, Harris CC and Bohr VA. **p53 modulates the exonuclease activity of Werner syndrome protein**. *Journal of Biological Chemistry* 276: 35093-35102, 2001. PMID: 11427532
217. Huo TI, **Wang XW**, Forgues M, Wu CG, Spillare EA, Giannini C, Brechot C. and Harris CC. Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis. *Oncogene* 20: 3620-3628, 2001. PMID: 11439325
218. Liu J, Akoulitchev S, Weber A, Ge H, Chuikov S, Libutti D, **Wang XW**, Conaway JW, Harris CC, Conaway RC, Reinberg D and Levens D. Defective interplay of activators and repressors with TFIIF in Xeroderma Pigmentosum. *Cell* 104: 353-363, 2001. PMID: 11239393
219. Yang Q, Manicone A, Coursen JD, Linke SP, Nagashima M, Forgues M, and **Wang XW**. Identification of a functional domain in a GADD45-mediated G2/M Checkpoint. *Journal of Biological Chemistry* 275: 36892-36898, 2000. PMID: 10973963
220. Yoo JY, **Wang XW**, Rishi AK, Lessor T, Xia XM, Gustafson TA and Hamburger AW. Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by heregulin. *British Journal of Cancer* 82: 683-690, 2000. PMID: 10682683
221. **Wang XW**. Role of p53 and apoptosis in carcinogenesis. *Anticancer Research* 19: 4759-4771, 1999. (review). PMID: 10697590
222. Mazur SJ, Sakaguchi K, Appella E, **Wang XW**, Harris CC and Bohr VA. Preferential binding of tumor suppressor p53 to positively or negatively supercoiled DNA involves the C-terminal domain. *Journal of Molecular Biology* 292: 241-249, 1999. PMID: 10493872.
223. Spillare EA, Robles AI, **Wang XW**, Shen JC, Yu CE, Schellenberg GD and Harris CC. p53-mediated apoptosis is attenuated in Werner Syndrome Cells. *Genes & Development* 13: 1355-1360, 1999. PMID: 10364153
224. Robles AI, **Wang XW** and Harris CC. Drug-induced apoptosis is delayed and reduced in XPD lymphoblastoid

- cell lines: possible role of p53 interaction with TFIID in the induction of apoptosis. *Oncogene* 18: 4681-4688, 1999. PMID: 10467415
225. Xu X, Weaver Z, Linke SP, Li C, Gotay J, **Wang XW**, Harris CC, Ried T and Deng CX. Centrosome amplification and a defective G2/M checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient mice. *Molecular Cell* 3: 389-395, 1999. PMID: 10198641
226. Zhou X, **Wang XW**, Xu L, Hagiwara K, Nagashima M and Harris CC. COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis. *Cancer Research* 59: 843-848, 1999. PMID: 10029073
227. Zhan Q, Antinore MJ, **Wang XW**, Carrier F, Smith ML, Harris CC and Fornace AJ Jr. Association with Cdc2 and inhibition of Cdc2/cyclin B1 kinase activity by the p53-regulated protein Gadd45. *Oncogene* 18: 2892-2900, 1999. PMID: 10362260
228. **Wang XW**, Coursen JD, Zhan Q, Fornace AJ, Jr and Harris CC. GADD45 induction of a G2-M cell cycle checkpoint. *Proc Nat'l Acad Sci USA* 96: 3706-3711, 1999. PMID: 10097101
229. Jia L, **Wang XW** and Harris CC. Hepatitis B virus X protein inhibits nucleotide excision repair. *International Journal of Cancer* 80: 875-879, 1999. PMID: 10074921
230. Parekh TV*, **Wang XW***, Makri-Werzen DM, Greenspan DS and Newman MJ. Type V collagen is an epithelial cell cycle inhibitor that is induced by and mimics the inhibitory effects of TGF- β 1. *Cell Growth & Differentiation* 9: 423-433, 1998. (*equal contribution). PMID: 9607563
231. **Wang XW** and Harris CC. p53 tumor-suppressor gene: clues to molecular carcinogenesis. *Journal of Cellular Physiology* 173: 247-255, 1997. (review). PMID: 9365531
232. **Wang XW** and Harris CC. p53 modulation of cell cycle and apoptosis. *Scanning Microscopy* 11: 953-965, 1997. (review).
233. Elmore LW, Hancock AR, Chang SF, **Wang XW**, Chang S, Callahan CP, Geller DA, Will H and Harris CC. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. *Proc Nat'l Acad Sci USA* 94: 14707-14712, 1997. PMID: 9405677
234. Buchhop S, Gibson MK, **Wang XW**, Wagner P, Sturzbecher HW and Harris CC. Interaction of p53 with the human Rad51 protein. *Nucleic Acid Research* 25: 3868-3874, 1997. PMID: 9380510
235. Adler V, Pincus MR, Minamoto T, Fuchs SY, Bluth MJ, Brandt-Rauf RW, Friedman FK, Robinson RC, Chen JM, **Wang XW** Harris CC and Ronai Z. Conformation-dependent phosphorylation of p53. *Proc Nat'l Acad Sci USA* 94: 1686-1691, 1997. PMID: 9050839
236. **Wang XW** and Harris CC. TP53 tumor suppressor gene: clues to molecular carcinogenesis and cancer therapy. *Cancer Surveys* 28: 169-196, 1996. (review). PMID: 8977035
237. Xu GW, Sun ZT, Forrester K, **Wang XW**, Coursen JD and Harris CC. Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wild-type p53 gene. *Hepatology* 24: 1264-1268, 1996. PMID: 8903408
238. **Wang XW**, Vermulen W, Coursen JD, Gibson MJ, Lupold SE, Forrester K, Xu G, Elmore L, Yeh H, Hoeijmakers JHJ and Harris CC. The XPB and XPD DNA helicases are components of the p53-mediated

apoptosis pathway. *Genes & Development* 10: 1219-1232, 1996. PMID: 8675009

239. Forrester K, Ambs S, Lupold SE, Kapust RB, Spillare EA, Weinberg WC, Felley-Bosco E, **Wang XW**, Geller DA, Billiar TR and Harris CC. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase (NOS2) expression by wild-type p53. *Proc Nat'l Acad Sci USA* 93: 2442-2447, 1996. PMID: 8637893
240. **Wang XW**, Gibson M, Vermulen W, Yeh H, Forrester K, Sturzbacher HW, Hoeijmakers JHJ and Harris CC. Abrogation of p53-induced apoptosis by the hepatitis B viral X gene. *Cancer Research* 55: 6012-6016, 1995. PMID: 8521383
241. Forrester K, Lupold SE, Ott VL, Chay CH, **Wang XW** and Harris CC. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. *Oncogene* 10: 2103-2111, 1995. PMID: 7784055
242. **Wang XW**, Yeh H, Schaeffer L, Roy R, Moncollin V, Egly JM, Wang Z, Friedberg EC, Evans MK, Taffe BG, Bohr VA, Weeda G, Hoeijmakers JHJ, Forrester K and Harris CC. p53 modulation of TFIIH associated nucleotide excision repair activity. *Nature Genetics* 10: 188-195, 1995. PMID: 7663514
243. **Wang XW**, Forrester K, Yeh H, Feitelson MA, Gu JR and Harris CC. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. *Proc Nat'l Acad Sci USA* 91: 2230-2234, 1994. PMID: 8134379
244. **Wang XW**, Lin XH, Klein CB, Bhamra RF, Lee Y-W and Costa M. A conserved region in human and Chinese hamster X chromosomes can induce cellular senescence of nickel-transformed Chinese hamster cell lines. *Carcinogenesis* 13: 555-561, 1992. PMID: 1576706
245. **Wang XW** and Costa M. Changes in protein phosphorylation in wild type and nickel-resistant cells and their involvement in morphological elongation. *Biological Metal* 4: 201-206, 1991. PMID: 1663778
246. Klein CB, Conway K, **Wang XW**, Bhamra RF, Lin XH, Cohen MD, Lois A, Barrett JC and Costa M. Senescence of nickel-transformed cells by a mammalian X chromosome: possible epigenetic control. *Science* 251: 796-799, 1991. PMID: 1990442
247. **Wang XW** and Costa M. Alteration of nickel binding proteins in nickel resistant cell. *Cancer Communication* 1(6): 351-358, 1989. PMID: 2702040
248. Imbra RJ, **Wang XW** and Costa M. Characterization of a nickel resistant mouse cell line. *Biological Trace Element Research* 21: 97-103, 1989. PMID: 2484637
249. **Wang XW**, Imbra RJ and Costa M. Characterization of mouse cell lines resistant to nickel (II) ions. *Cancer Research* 48: 6850-6854, 1988. PMID: 3180093
250. Zelikoff JT, Li JH, Hartwig A, **Wang XW**, Costa M and Rossman TG. Genetic toxicology of lead compounds. *Carcinogenesis* 9: 1727-1732, 1988. (review). PMID: 3168150
251. Conway K, **Wang XW**, Xu L and Costa M. Effect of magnesium on nickel-induced genotoxicity and cell transformation. *Carcinogenesis* 8: 1115-1121, 1987. PMID: 3301046
252. Sugiyama, M., **Wang, X. W.** and Costa, M.: Comparison of DNA lesions and cytotoxicity induced by calcium chromate in human, mouse and hamster cell lines. *Cancer Research* 46: 4547-4551, 1986. PMID: 3731109
253. **Wang XW**, Shen ZM, Yang JL and Xu B. Inhibitory effect of hydroxycamptothecin on colony formation of

KB cells and DNA damage. *Yao Xue Xue Bao* 21: 492-7, 1986. PMID: 3811937

254. **Wang XW**, Yu WJ, Shen ZM, Yang JL and Xu B. Cytotoxicity of hydroxycamptothecin and four other antineoplastic agents on KB cells. *Zongguo Yao Li Xue Bao* 8: 86-90, 1987. PMID: 2955666
255. **Wang XW**, Yue XF, Han JX, Wu FG, Shen ZM, Xu B and Huang CC. Studies on cytotoxicity and induction of sister chromatid exchanges in V79 cells with three antitumor agents. *KEXUE TONGBAO* 29: 1268-1271, 1984.
256. Huang CC, Han JX, Yue XF, Shen ZM, **Wang XW**, Wu FG and Xu B. Cytotoxicity and sister chromatid exchanges induced *in vitro* by six anticancer drugs developed in the People's Republic of China. *Journal of National Cancer Institute* 71: 841-847, 1983. PMID: 6413744

Book Chapters

1. Xu B, **Wang XW**, Han JX and Huang CC. Cytotoxicity and induction of sister chromatid exchanges (SCE) *in vitro* by several antitumor drugs. In: *Mutation, Cancer and Malformation*, Chu EHY and Generoso WM eds, Plenum, NY, pp. 819, 1984.
2. Costa M, Conway K, Imbra R and **Wang XW**. The involvement of heterochromatin damage in nickel-induced transformation and resistance. In: *Nickel and Human Health: Current Perspectives*, Nieboer, E. and Antio, A., eds., John Wiley and Sons, Inc., NY, Advances in Environmental Science and Technology, 1990.
3. Costa M, Christie NT, Cantoni O, Zelikoff JT, **Wang XW** and Rossman TG. DNA damage by mercury compounds, an overview. *Advances in Mercury Toxicology*, Suzuk ed, Plenum, NY, pp. 255-273, 1991.
4. Jia L, **Wang XW**, Sun Z and Harris CC. Interactive effects of p53 tumor suppressor gene and hepatitis B virus in hepatocellular carcinogenesis. In: *Molecular Pathology of Gastroenterological Cancer: application to clinical practice*. Tahara E ed., Springer-Verlag, Tokyo, pp. 209-218, 1997.
5. **Wang XW**, Greenblatt MS and Harris CC. Molecular genetics of lung cancer. In: *Clinical and Biological Basis of Lung Cancer Prevention*. Martinet Y, Hirsch FR, Martinet N, Vignaud J-M, Mulshine JL, eds, Birkhauser Verlag, Basel, pp. 117-127, 1998.
6. Hussain SP, **Wang XW**, Shields PG and Harris CC. Gene-environment interactions in human cancer risk. In: *Chemicals in the 21st century, chemicals for sustainable development*. Proceedings of the Fourth Princess Chulabhorn International Science Congress. Bangkok, Trinity Publ. Co., pp. 39-49, 1999
7. **Wang XW**. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. In: *Methods in Molecular Medicine, vol. 45: Hepatocellular Carcinoma Methods and Protocols*, Habib N ed. Humana Press Inc. Totowa, NJ, 57-70, 2000.
8. Hofseth LJ, Hussain SP, **Wang XW** and Harris CC. Hepatocellular Cancers: Molecular biology and genetics. In: *Principles and Practices of Gastrointestinal Oncology*. Kelsen DP, Daly J, Levin B, Tepper J, Kern S Eds. Philadelphia, Lippincott Williams & Wilkins, pp. 539-558, 2002.
9. Elmore LW, **Wang XW**, Harris CC. Hepatocellular Carcinoma. In: *Encyclopedia of the Human Genome*, Cooper DN Ed. Nature Publishing Group. pp. 216-220, 2003.
10. Budhu A and **Wang XW**. The Role of Hepatitis Viruses in Liver Oncogenesis. In: *Recent Research Developments in Molecular Biology*. Pandalai SG Ed. Research Signpost, 1: 97-118, 2003.

11. Budhu A and **Wang XW**. Human hepatocellular carcinoma: New insights from gene expression profiling. In: *Progress in Liver Cancer Research*. Columbus F Ed. Nova Science Publishers, Inc, 2006.
12. Budhu A and **Wang XW**. The role of nucleophosmin in Ran/Crm1-mediated centrosome duplication. *Center for Cancer Research Frontiers in Science*, 5, 2006
13. Budhu A and **Wang XW**. The functional relevance of HBx subcellular localization and nuclear shuttling. In: *The pleiotropic functions of the viral protein HBx in Hepatitis B virus infection and the development of liver cancer*. J Kobarg Ed. Research Signpost, 2008.
14. Hussain SP, **Wang, XW**, Harris CC. Inflammation and human cancer. In: *Pathogenesis and clinical practice in gastroenterology*. Ed. Lancaster Publishing Services, United Kingdom, 137-48, 2008.
15. Budhu A and **Wang XW**. Genome-wide expression profiling of human hepatocellular carcinoma. In: *The Liver: Biology and Pathobiology*, 5th edition. Arias I, Ed. Wiley/London Publisher, 2009.
16. Budhu A, Ji J and **Wang XW**. Genomic profiling of human hepatocellular carcinoma. In: *Hepatocellular cancer: diagnosis and treatment*, 2nd edition. Carr BI, Ed. Humana Press Inc, 2009.
17. Budhu A and **Wang XW**. Molecular signatures of hepatocellular carcinoma metastasis. In: *Molecular genetics of liver neoplasia*, 1st edition. Wang XW, Grisham JW and Thorgeirsson SS, Eds. Springer, New York, NY, 2010
18. Grisham JW, **Wang XW**, Thorgeirsson SS. Overview of cholangiocarcinoma and evidence for a primary liver carcinoma spectrum. In: *Molecular genetics of liver neoplasia*, 1st edition. Wang XW, Grisham JW and Thorgeirsson SS, Eds. Springer, New York, NY, 2010
19. **Wang XW**, Grisham JW, Thorgeirsson SS. Biology of Hepatocellular carcinoma: past, present and beyond. In: *Molecular genetics of liver neoplasia*, 1st edition. Wang XW, Grisham JW and Thorgeirsson SS, Eds. Springer, New York, NY, 2010
20. Ji J, **Wang XW**. MicroRNAs in Hepatocellular Carcinoma. In: *MicroRNAs in Cancer Translational Research*. Cho W Ed., Springer, New York, NY 2011.
21. Ji J, **Wang XW**. Identification of Cancer Stem Cell-Related MicroRNAs in Hepatocellular Carcinoma. In: *Liver Stem Cells: Methods and Protocols*. Ochiya T Ed., Humana, 2011
22. Zhao X, Elmore LW, Harris CC, and **Wang XW**. Hepatocellular Carcinoma. In: *eLS*. John Wiley & Sons, Ltd: Chichester, 2011
23. Zhao X, **Wang XW**. Exploration of cytokine signaling in clinical management of hepatocellular carcinoma. In: *From Inflammation to Cancer: Advances in Diagnosis and Therapy for Gastrointestinal and Hepatic Diseases*. Eds., Cho CH, Yu J, World Scientific and Imperial College Press, Singapore, 2012
24. Budhu A, **Wang XW**. Genomic profiling of human hepatocellular carcinoma. In: *Hepatocellular cancer: diagnosis and treatment*, 3rd edition. Carr BI, Ed. Humana Press Inc, 2016.
25. Wei X, Liu N, **Wang XW**, Ji Ji. Genomics studies in hepatocellular carcinoma via next generation sequencing. In: *Molecular Pathology of Liver Cancer*. Chen Liu, Ed. Springer, New York, NY 2018

26. Fako V, **Wang XW**. Molecular carcinogenesis of HBV-related HCC. In: *Hepatitis B Virus and Liver Disease*. Kao JH, Chen DS, Eds, Springer, Singapore, 2018
27. Hung MH, **Wang XW**. Molecular alterations and heterogeneity in hepatocellular carcinoma. In: *Hepatocellular Carcinoma: Translational Precision Medicine Approaches*. Hoshida Y, Ed. Humana Press, 2019; PMID: 32078265
28. Dominguez DA and **Wang XW**. Therapeutic Drug Screening Using a Three-Dimensional Organotypic Model of Hepatocellular Carcinoma. Sanders J, Chen X, Eds, Springer 2022
29. Craig AJ and **Wang XW**. Molecular Carcinogenesis of Hepatitis B Virus-Related Hepatocellular Carcinoma. In: *Hepatitis B Virus and Liver Disease*. Gao JH, Ed. Springer Nature 2022